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  อภยั  ดวงค า : การทดสอบความเป็นพิษของฟลาโวนอยด์บางชนิดและยาปฏิชีวนะ
ในกลุ่มเบตาแลคแทม ในสัตวท์ดลอง (IN VIVO TOXICITY TEST OF SOME 
FLAVONOIDS AND β-LACTAM ANTIBIOTICS) อาจารยท่ี์ปรึกษา :                   
ผูช่้วยศาสตราจารย ์ดร.เกรียงศกัด์ิ  เอ้ือมเก็บ, 107 หนา้. 
 
             ฟลาโวนอยดเ์ป็นสารประกอบในกลุ่มโพลีฟีนอลท่ีเกิดข้ึนเองตามธรรมชาติซ่ึงพบ
ไดใ้นผลไมแ้ละผกั ฟลาโวนอยด์เป็นส่วนประกอบส าคญัของอาหารท่ีเรารับประทานเป็นประจ า
และมีฤทธ์ิทางเภสัชวิทยาท่ีหลากหลายโดยเฉพาะอย่างยิ่งฟลาโวนอยด์สามารถเสริมฤทธ์ิกบัยา
ปฏิชีวนะในกลุ่มเบตาแลคแทม ตา้นเช้ือแบคทีเรียด้ือยาได ้อยา่งไรก็ตาม ยงัไม่มีรายงานการศึกษา
ความเป็นพิษของฟลาโวนอยด์ในสัตวท์ดลอง ดงันั้นวตัถุประสงคข์องการวิจยัคร้ังน้ี เพื่อศึกษาพิษ
ก่ึงเฉียบพลนัและพิษก่ึงเร้ือรังของฟลาโวนอยด์ 5 ตวัคือ เคอร์เซติน ไบคาลิน เอพิจีนิน ลูทีโอลิน 
และกาแลนจิน เม่ือใชเ้ด่ียวและผสมกบัยาคลอกซาซิลินหรือเซพทาซิดีนในหนูถีบจกัร วิธีการศึกษา
พิษก่ึงเฉียบพลนัโดยฉีดสารต่อไปน้ีเขา้ช่องทอ้งเป็นเวลา 14 วนั ไดแ้ก่ เคอร์เซติน ไบคาลิน เอพิจี
นิน ลูทีโอลิน และกาแลนจินเด่ียวๆ ขนาด (ปกติและสูง) 20 และ 80, 10 และ 40, 20 และ 80, 1 และ 
4, 10 และ 40 มิลลิกรัมต่อกิโลกรัม (น ้ าหนกัตวั) ต่อวนั ตามล าดบั และฉีดเคอร์เซตินหรือไบคาลิน 
ผสมกบัคลอกซาซิลิน ขนาด (ปกติ, สูง) 20+150, 80+600 และ 10+150, 40+600 มิลลิกรัมต่อ
กิโลกรัม (น ้าหนกัตวั) ต่อวนั ตามล าดบั ส่วนเอพิจีนิน ลูทีโอลิน และกาแลนจินผสมกบัเซพทาซีดีน 
ขนาด (ปกติ, สูง) 20+160, 80+640; 1+160, 4+640 และ 10+160, 40+640 มิลลิกรัมต่อกิโลกรัม 
(น ้าหนกัตวั) ต่อวนั ตามล าดบั วธีิการศึกษาพิษก่ึงเร้ือรังโดยฉีดสารต่อไปน้ีเขา้ช่องทอ้งเป็นเวลา 90 
วนั ไดแ้ก่ เคอร์เซติน ไบคาลิน เอพิจีนิน และลูทีโอลินเด่ียวๆ ขนาด (ปกติและสูง) 20 และ 40, 10 
และ 20, 20 และ 40, 1 และ 2 มิลลิกรัมต่อกิโลกรัม (น ้ าหนกัตวั) ต่อวนั ตามล าดบั และฉีดเคอร์เซ
ตินหรือไบคาลิน ผสมกบัคลอกซาซิลิน ขนาด (ปกติ, สูง) 20+150, 40+300 และ 10+150, 20+300 
มิลลิกรัมต่อกิโลกรัม (น ้ าหนักตวั) ต่อวนั ตามล าดบั ส่วนเอพิจีนิน หรือลูทีโอลินผสมกบัเซพทา
ซีดีน ขนาด (ปกติ, สูง) 20+160, 40+320 และ 1+160, 2+320 มิลลิกรัมต่อกิโลกรัม (น ้ าหนกัตวั) ต่อ
วนั ตามล าดบั ภายหลงัส้ินสุดการทดลองไดน้ าอวยัวะท่ีส าคญัและเลือดมาวิเคราะห์ผลทางชีวเคมี
และโลหิตวทิยาทั้งพิษก่ึงเฉียบพลนัและพิษก่ึงเร้ือรัง พบวา่ น ้ าหนกัสัมพทัธ์และน ้ าหนกัของอวยัวะ
ส าคญั (ต่อน ้ าหนกัตวั) ไดแ้ก่ หวัใจ ตบั มา้ม ปอด ไต และกระเพาะอาหาร และผลการตรวจสอบ
ชีววทิยาของเน้ือเยื่อของหนูทดลองไม่มีการเปล่ียนแปลงอยา่งมีนยัส าคญัทางสถิติ เม่ือเปรียบเทียบ
กบักลุ่มควบคุม ส่วนผลทางชีวเคมีและโลหิตวิทยาของการทดสอบพิษก่ึงฉับพลนัและก่ึงเร้ือรัง 
พบวา่ เคอร์เซติน เอพิจีนิน และลูทีโอลีน ไม่มีพิษต่อพารามิเตอร์เหล่าน้ี ยกเวน้ กาแลนจินท าให้ค่า
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เอชซีทีลดลง และไบคาลินท าให้ค่าเอ็มซีวีลดลง เม่ือให้สารเหล่าน้ีในขนาดปกติ เป็นเวลา 14 วนั 
นอกจากน้ี เอพิจีนินขนาดสูงและให้เป็นเวลานานจะท าให้ค่าเม็ดเลือดขาวและเอ็มซีวีลดลง ส่ิงท่ี
น่าสนใจอยา่งยิง่คือ สารฟลาโวนอยด์เหล่าน้ีสามารถลดคอเลสเตอรอลในเลือดของหนูทดลอง เม่ือ
ให้ในปริมาณสูงและเป็นเวลานาน ค่าคอเลสเตอรอลท่ีลดลงในหนูทดลองท่ีได้รับไบคาลินนั้น
สอดคลอ้งกบัผลจากเอฟทีไออาร์ ท่ีองคป์ระกอบของโครงสร้างทุติยภูมิของเอไมด์วนัลดลง ผลท่ี
ไดจ้ากการศึกษาคร้ังน้ี จะเป็นขอ้มูลท่ีเป็นประโยชน์ในการทดสอบความเป็นพิษในสัตวเ์ล้ียงลูก
ดว้ยนมชั้นสูงรวมทั้งในคน  
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APHAI DUANGKHAM : IN VIVO TOXICITY TEST OF SOME 
FLAVONOIDS AND β-LACTAM ANTIBIOTICS. THESIS ADVISOR : 
ASST. PROF. GRIANGSAK  EUMKEB, Ph.D.  107 PP. 
FLAVONOIDS/β-LACTAM ANTIBIOTICS/SUBACUTE TOXICITY/ 
SUBCHRONIC TOXICITY 
Flavonoids are part of a family of naturally occurring polyphenolic 
compounds and represent one of the most prevalent classes of compounds in 
vegetables and fruits. Flavonoids are important constituents of normal human diet and 
also have various pharmacological properties. Especially, flavonoids have synergistic 
activity with β-lactam antibiotic against drugs resistant bacteria. However, in vivo 
toxicity test of these flavonoids have not been studied. Thus, the purpose of this study 
was to investigate the subacute and subchronic toxicity of five flavonoids (quercetin, 
baicalein, apigenin, luteolin, and galangin) alone and in combination with cloxacillin 
or ceftazidime antibiotics in mice. In subacute toxicity test, the mice were 
administered intraperitoneally (i.p.) with the following flavonoids and/or drugs: 
(normal and high dose) 20 and 80 mg/kg BW/day of both quercetin and apigenin, 10 
and 40 mg/kg BW/day of baicalein, 1 and 4 mg/kg BW/day of luteolin, and 10 and 20 
mg/kg BW/day of galangin when used singularly. In addition,  quercetin plus 
cloxacillin at 20+150, 80+600; baicalien plus cloxacillin at 10+150, 40+600 mg/kg 
BW/day, and apigenin; luteolin; or galangin in combination with ceftazidime at 
20+160, 80+640;  1+160, 4+640; or 10+160, 20+640 mg/kg BW/day, respectively. In 
the subchronic toxicity test, the mice were injected (i.p.) with the following 
flavonoids and/or drugs: 20 and 40 mg/kg BW/day of quercetin or apigenin, 10 and 
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20 mg/kg BW/day of baicalein, and 1 and 2 mg/kg BW/day of luteolin alone. 
Moreover, the combinations of quercetin or baicalien plus cloxacillin at 20+150, 
40+300; or 10+150, 20+300 mg/kg BW/day, respectively. Furthermore, apigenin or 
luteolin in combination with ceftazidime at 20+160, 40+320; or 1+160, 2+320, 
respectively. At the end of the experiments, blood and the selected main organs were 
collected for haematological and histological analyses. The results showed that there 
were no significant difference in either the relative growth rate of total body weight or 
weight of the selected main body organs of mice such as heart, liver, spleen, lung, 
kidney, stomach, and their histology treated with all doses of five flavonoids using 
singly and in combinations when compared to the control. The blood chemistry and 
haematological analysis of subacute toxicity and subchronic toxicity showed that 
quercetin, apigenin and luteolin exhibited no toxicity in these parameters except for 
galangin caused Hct decrease and baicalein resulted in MCV reduction when these 
flavonoids were administered at therapeutic dose for 14 days. Moreover, apigenin at 
high dose and long duration led to WBC and MCV decrease. Interestingly, These 
flavonoids provide evidence that its can reduce cholesterol in mice blood when 
administered at high dose and long duration. The lowering of cholesterol in baicalein 
treated mice are substantial agreement with the result from FTIR that the amide I 
secondary structure component was decreased. In summary, this study could be useful 
information for further investigation of toxicity in higher mammal animals, including 
human beings. 
School of Biology Student’s Signature                                   
Academic Year 2011 Advisor’s Signature    
 Co-Advisor’s Signature    
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 CHAPTER I 
INTRODUCTION 
 
1.1 Introduction 
Bacterial resistance to antibiotics is a serious global problem. Strains of β-
Lactam-resistant Staphylococus aureus including methicillin-resistant S. aureus 
(MRSA) and strains of ceftazidime-resistant Enterobacter cloacae (CREnC) now 
pose serious problem to hospitalized patients, and their care providers (Mulligan et 
al., 1993).  New approaches to resolve this problem are needed. Active compounds 
from medicinal plants have long been isolated to use for multipurpose, including 
antibiotic purpose.   
Flavonoids are polyphenolic compounds found as integral components in the 
human diet. They are generally found in fruit, vegetables, grains, bark, stems, roots, 
wine, and tea. The beneficial effects of these natural compounds have been long 
studied in a variety of methodologies. More than 4,000 varieties of flavonoids have 
been identified, many of which are responsible for attractive colors of flowers, leaves, 
and fruits. It is widely accepted that the high intake of foods and beverages rich in 
polyphenols, especially in flavonoids, has been associated with decreased risk of 
coronary heart disease and also inhibited the proliferation of various tumor growth. 
Furthermore, epidemiologic studies suggested a protective role of dietary flavonoids 
against cancer induction in several human tissues, including colon, lung, prostate, and 
urinary bladder (Lakhanpal and Rai, 2007).  
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Flavonoids can be divided into various classes on the basis of their molecular 
structure. Some major classes of flavonoids and their chemical structures are shown in 
Table 1.1 and Figure 1.1, respectively. 
 
Table 1.1 Some major classes of flavonoids, examples of individual flavonoids and 
their food sources.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Moon et al. (2006). 
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Figure 1.1  Structures of the major classes of flavonoids. 
    Source: Lakhanpal and Rai (2007). 
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The combination between antibiotics and active compounds from medicinal 
plants are the new approach against the resistant bacteria. Recent studies have been 
reported the synergistic antibacterial activity of flavonoids and antibiotics (Cushine 
and Lamb, 2006). There were growing evidence that flavonoids in combination with 
antibiotics interfere with various bacterial virulence factors, incuding enzymes, toxins 
and signal receptors (Cushine and Lamb, 2005; Eumkeb et al., 2008). The synergistic 
activity of galangin and ceftazidime againt ceftazidime resistant S. aureus may 
involve three mechanisms of action by galangin. The first is on the integrity of the cell 
wall and on septum formation prior to cell division. This implies an effect on protein 
synthesis including an effect on penicillin-binding protein 2a (PBP 2a). The second 
mechanism of galangin activity is via inhibition of the activity of certain penicillinase 
enzyme by interaction with this enzyme. The third is galangin causes cytoplasmic 
membrane damage results in potassium loss (Eumkeb et al., 2010). However, in vivo 
toxicity test of some potential flavonoids have not been studied. Thus, the purpose of 
this thesis was to investigate the toxicity of flavonoids alone and in combination with 
antibiotics in vivo. This study may help us to clearify in vivo toxicity of these 
flavonoids when used alone or in combination with antibiotics certain.  
 
1.2    Research objectives  
1.2.1 To investigate the toxicity of flavonoids in mice when used alone and in 
combination with β-lactams antibiotics. 
1.2.2 To investigate the serum biological changes of flavonoids alone and 
flavonoids plus β-lactam antibiotics treated mice by using infared microspectroscopy 
with multivariate data analysis. 
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1.3 Research hypothesis 
 These flavonoids when administrated singly and in combination with β-lactam 
antibiotics in mice do not show any toxicity. 
 
1.4 Scope and limitation of the study 
1.4.1 IRC male and female mice matched for age and weight were purchased 
from National laboratory Animal Center, Salaya Campus, Mahidol University, 
Thailand. 
1.4.2 All tested flavonoids (apigenin, baicalein, luteolin and quercetin) were 
obtained from Indofine Chemical Company, USA. 
1.4.3 Ceftazidime and cloxacillin were obtained from Sigma-Aldrich, USA. 
 
1.5 Expected results 
1.5.1 Data of subacute and subchronic toxic effects of some flavanoids on mice 
when used alone and in combination with β-lactams antibiotics would be clarified. 
1.5.2 These toxicities information would be useful for further investigation in 
other higher mammal animals. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Overview of toxicity and definition of key terms 
2.1.1 Definition of toxicity 
Toxicity is defined as “the potential of a substance to exert a harmful 
effect on humans or animals, and a description of the effect and the conditions or 
concentration under which the effect takes place” (Health and Safety, 2004). In order 
to support an application for a clinical trial or for the registration of a new drug, it is 
necessary to satisfy legislation that requires certain data produced from a variety of 
toxicological investigations that show the safety profile of the compound to which 
humans may be exposed. Therefore, in the majority of cases of evaluation of the 
toxicity of most substances, rodents and non-human primates are first used in 
preclinical animal safety studies before further studies are done in humans. These 
animals are mainly used because of their biological similarity to humans that allows 
them to be regarded as the suitable metabolic models for humans in a broad range of 
investigations (Loomis and Hayes, 1996; Pascoe, 1983). 
 In general, toxicity testing methods can be divided into two categories: 
The first category is designed to evaluate the overall effects of compounds on 
experimental animals. Individual test in this category differs from each other basically 
in regard to the duration of the test and the extent to which the animals are evaluated
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for general toxicity. These tests are classified as acute, prolonged and chronic toxicity 
tests (Loomis and Hayes, 1996). The second category consists of those that are 
designed to evaluate specific types of toxicity in detail. The prolonged and chronic 
tests do not detect all forms of toxicity, but they may reveal some of the specific 
toxicities and indicate the need for more detailed studies. Thus, this second category 
of tests has been developed for determination effects of compounds on the fetus in a 
pregnant animal (teratogenic tests), on the reproductive capacity of the animals 
(reproduction tests), on the genetic system (mutagenic tests), for the determination of 
the ability of agents to produce tumors (tumorigenicity and carcinogenicity tests) 
(Timbrell, 2002). 
Acute and chronic toxic effects differs principally from each other with 
respect to the amount of chemical compound involved and the time intervening before 
the effect is seen (Timbrell, 2002). Acute effects are normally observed soon after 
exposure and result from the uptake of large amounts of poison, generally as a single 
dose. On the other hand, chronic effects are often detected over an extended period of 
time during which exposure may be continuous or intermittent, though obviously at 
levels which are too low to produce an acute effect (Loomis and Hayes, 1996; Pascoe, 
1983). 
 
2.1.1.1 Acute toxicity tests 
Acute toxicity is those designed to determine the effects which 
occur within a short period after dosing. These tests can determine a dose-response 
relationship and the LD50 value if required (Timbrell, 2002). 
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2.1.1.2 Chronic toxicity tests 
 These tests involve exposure animals with interested compounds 
for at least 12 months to 2 years in rodents (about 50 percent lifespan) and 6-12 
months in non-rodents. Chronic toxicity tests may be combined with in vivo 
carcinogenicity tests, in which case the exposure of rodents will be lifetime, and 
satellite groups may be used for interim chronic toxicity information. There is 
currently discussion in the International Committee on Harmonization as whether 
chronic toxicity tests need to be as long as 2 years or whether shorter time will yield 
as much information (Timbrell, 2002). 
The purpose of the chronic toxicity test is to investigate the 
harmful effects that foreign compounds that are introduced to animals in repeated 
doses or in continuous exposure over an extended period of time may produce (Poole 
and Leslie, 1989). As with sub-chronic toxicity tests, the chronic toxicity tests will 
terminate with a pathological examination and there many also be clinical chemical 
measurements made throughout at intervals. These clinical chemical measurements 
can indicate the development of pathological changes which can then be detected at 
post-mortem (Timbrell, 2002). Different approaches to dose ranging studies are 
applied depending on the species being used. The procedures used can vary, but 
usually involve exposing the experimental animals (in typical group sizes of two to 
five animals/sex/group) to various doses of the test compound, i.e. from the maximal 
non-lethal dose (determined in the acute studies) down to doses in the 
pharmacological dose range. Clinical chemistry and hematological parameters are 
then measured at the start of the study (i.e. within 48 hours after the first dose) and at 
the end of the study, along with full histopathology analysis of all abnormal tissues 
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plus the major organs (such as the heart, liver, kidneys, lungs and brain of the 
animals), at least at the end of the study (Poole and Leslie, 1989; Timbrell, 2002). 
 
2.1.2  Toxic effects 
                    Toxic effects are defined as “harmful responses of a biological system to 
a toxic compound, and death of cells or the whole organism are the major response 
(Timbrell, 2002). 
                     In all the cases, the toxic effects are usually manifested either in an acute 
or a chronic manner, and occur mostly as a result of an acute or chronic exposure to 
toxic compound by oral ingestion, inhalation or absorption following skin contact 
(Hui et al., 2008). The toxic effects are seen as (1) signs or reflection of a disturbance 
of the normal activities of enzymes that perform essential biochemical roles in all 
forms of life; (2) alteration of the normal activities of plasma membrane that regulate 
the exchange of nutrients and metabolites between the cell and its surroundings and 
(3) the disturbances of other normal cell activities, e.g. RNA and DNA synthesis, 
growth, division and general metabolism at all levels of organization from sub-
cellular to organ and organ system (Timbrell, 2002). 
 
2.2 Routes of administration 
This term refers to the way in which drugs or compounds are introduced to 
animals or humans. To evaluate toxicity of a compound in animals various routes may 
be used, but two most commonly used modes of administration for animals studies are 
via intraperitoneal injection or the oral route (Poole and Leslie, 1989). 
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 2.2.1  Intra-peritoneal injection 
                  This is one of the methods of dosing, which may occasionally provide 
information about local as well as systemic toxicity. To give drugs by intraperitoneal 
dosing, the animal is laid on its back and the abdomen shaved. This area is thoroughly 
cleaned and, using an appropriate syringe and needle, the abdominal wall is 
punctured. To ensure minimal danger of perforation of abdominal viscera, the 
injection should be made rostral and lateral to the bladder at an angle of about 15º to 
the abdomen. The depth of penetration should not exceed 5mm (Poole and Leslie, 
1989; Waynforth, 1980).  
 
 2.2.2 Oral administration 
 The oral route is probably one of the most common means by which a 
chemical enters the body. In short, the oral administration is the form of 
administration involving the gastrointestinal tract, which may be viewed as a tube 
going through the body, starting at the mouth and ending at the anus. Although it is 
within the body, its contents are essentially exterior to the body fluids. Most orally 
administered chemicals can otherwise have a systemic effect on the organism only 
after absorption has occurred from the mouth or the gastrointestinal tract. Oral 
administration of chemicals that are rapidly absorbed from the gastrointestinal tract 
would theoretically expose the liver to concentrations of the agent that would not be 
obtained if other routes of administration were used (Loomis and Hayes, 1996). 
Furthermore, if a compound entered the enterohepatic cycle, at least a portion of the 
compound would be localized in the organs involved in the cycle. Compounds that are 
known to be toxic to the liver would be expected to be more toxic following oral 
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administration on repeated occasions, whereas their administration by other routes 
may be less hazardous (Loomis and Hayes, 1996; Waynforth, 1980). 
 
2.3 Current use and importance of flavonoids 
Flavonoids are a structurally diverse class of polyphenolic compounds 
ubiquitously found among plants and produced as a result of plant secondary 
metabolism (Tsuji and Walle, 2008). The term, phenolic compound, embraces a wide 
range of chemical constituents possessing an aromatic ring bearing one or more 
hydroxyl substituents in common. It is estimated that about 2% of all carbon 
photosynthesized by plants is converted into flavonoids or closely related compounds. 
They are virtually ubiquitous in green plants in which they are often responsible for 
the coloration of flowers, fruits and leaves. Their occurrence are however not 
restricted to the latter organs but include all parts of the plant, roots, wood, bark and 
nectar. As such, flavonoids constitute one of the most characteristic classes of 
compounds that are likely to be encountered in any work involving plant extracts 
(Markham, 1982; Harborne, 1973). In particular, ﬂavonoids are becoming the subject 
of medical research. They have been reported to possess many useful properties, 
including anti-inﬂammatory activity, oestrogenic activity, enzyme inhibition, 
antimicrobial activity, antiallergic activity, antioxidant activity, vascular activity and  
cytotoxic antitumour activity. For a group of compounds of  relatively  homogeneous  
structure,  the ﬂavonoids inhibit a perplexing number and variety of eukaryotic 
enzymes and have a tremendously wide range of activities. In the case of enzyme 
inhibition, this has been postulated to be due to the interaction of enzymes with 
different parts of the ﬂavonoid molecule, e.g. carbohydrate, phenyl ring, phenol and 
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benzopyrone ring (Cushinie and Lamb, 2005; 2006). Previous finding showed that 
galangin, quercetin and baicalein revealed the potential to reverse bacterial resistance 
to β-lactam antibiotics against penicillin-resistant S. aureus (PRSA). These could 
involve three mechanisms of action that galangin inhibit protein synthesis and effect 
on PBP 2a, interact with penicillinase and cause cytoplasmic membrane damage 
(Eumkeb et al., 2010).  
 
2.4 Chemistry and classification 
  The term of flavonoids is a collective noun for plant pigments, mostly derived 
from benzo-γ-pyrone. Flavonoids are part of a family of naturally occurring 
polyphenolic compounds and represent one of the most prevalent classes of 
compounds in vegetables, nuts, fruits and beverages such as coffee, tea, and red wine 
as well as medical herbs. More than 8,000 compounds with a flavonoid structure have 
been identified. The classes of flavonoids include chalcones, flavones, flavonols, 
flavanols, anthocyanins and isoflavones (Cushinie and Lamb, 2005). 
 
2.5 The pharmacology of flavonoids in animals   
2.5.1 Biological properties of apigenin 
 
 
 
                     Molecular formula : C15H10O5 
Solubility : Soluble in hot alcohol and dimethylsulfoxide 
(DMSO), insoluble in water 
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Melting point : 345-350 
o
C 
Appearance : Yellow needle  
(Susan, 1996)  
Apigenin is a flavonoid found in artichoke, basil, celery and other plants. 
It is widely used as inhibiting the prostate cancer and skin tumor promotion. Kuo, Lee 
and Lin (1992) reported that apigenin can inhibit the bacterial mutagenesis induced by 
nitropyrene and also protected against the cytotoxicity induced by 1-nitropyrenene 
and 1, 6-dinitropyrene and gave a significant reduction of the frequency of sister 
chromatid exchange. In addition, Oksus et al. (1984) investigated that the MIC for 
apiginin against Proteus vulgaris, Pseudomonas aeruginosa, Escherichia coli and 
Klebsiella pnemoniae ranged from 54 to 219 µg/mL and that apiginin also proved to 
be active against the spore-former Bacillus subtilis. 
  
2.5.2 Biological properties of baicalein 
 
   
 
                          
Molecular formular : C15H10O5 
Solubility : Soluble in alcohol, methanol, ether, acetone,  ethyl      
        acetate, hot glacial acetic acid and DMSO 
Melting Point : 264-265
  o
C 
Appearance : Yellow needle and light yellow powder                     
(Susan, 1996)  
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The dried roots of Scutellaria baicalensis have been used as Chinese 
traditional plant for antibacterial and antivirus agents. Wang et al. (2004) indicated 
that baicalein played a protective role in β-amyloid peptide-(25-35)-induced amnesia. 
Furthermore, baicalein exhibited strong inhibition of transport of tetracycline with 
membrane vesicles prepared from Escherichia coli KAM32/pTZ1252 (Fujita et al., 
2005). In addition, baicalein has been effective in anti-flammatory, anti-tumor and 
also induction of apoptosis in several human prostate cancer cell lines (Chan et al., 
2000). Baicalin has the synergistic effect with benzylpenicillin which showed the 
killng of MRSA and β-lactam-resistant S. aureus (Liu et al., 2000). 
 
2.5.3 Biological properties of galangin 
 
   
 
 
 
Molecular formular : C15H10O5 
Solubility : Soluble in chloroform, benzene, ethanol, ether, and  
       DMSO 
Melting point : 214-215 
o
C 
    Appearance : Yellowish needle (Susan, 1996) 
 It is generally accepted that galangin is a flavonol that does not have any 
hydroxyl group in the B ring and has been suggested to be a substrate of cytochrome 
P450 which, through the hydroxyl of the B ring, could metabolise it to more 
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genotoxic products. Galangin have been reported to have anti-gram-positive bacteria 
with the minimum inhibitory concentration (MIC) ranging from 0.1 to 0.5 µg/ml, and 
also against Enterobacter cloacae which was significantly inhibited at a MIC of 0.1 
mg/ml. Eumkeb and Richards (2003) reported that amoxicillin plus galangin 12.5 
µg/ml can inhibit twelve clinical isolates of resistance S. aureus and four isolates of 
methicillin-resistance S. aureus. The combination of galangin at 5 µg/ml plus 
ceftazidime at 5 µg/ml showed synergistic effect by reducing the CFµ/ml of 
penicillin-resistant S. aureus (PRSA) to 1 x 10
3
 over 6 and throughout 24 h. 
Electronmicroscopy clearly revealed that the combination of galangin and ceftazidime 
caused damage to the ultrastructures of the cells of this bacterial strain (Eumkeb et al., 
2010). Galangin has the antibacterial activity against 4-quinolone resistant S. aureus 
at MICs of 50 µg/ml (Cushine and Lamb, 2006). 
 
2.5.4 Biological properties of luteolin 
 
 
 
                  
        
Molecular formular : C15H10O6 
Melting point : 328-330 
o
C 
Solubility : Soluble in ethyl acetate, formic acid, water, alkaline  
       and DMSO 
                                   Appearance : Yellow needle (Susan, 1996) 
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Luteolin is a flavone that is found in foods including, parsley, artichoke 
leaves, celery, citrus fruits, sage, thyme and many others. There are numerous reports 
on biological activities of luteolin, for example, antioxidant, anti-inflammatory, anti-
allergic, anticancer activities and immune-modulating properties to suppress 
hyperactive immune systems (Shimoi et al., 1998; Mino et al., 2004). In addition, 
luteolin is an antimutagenic and antitumorigenic agent, an inhibitor of protein kinase 
C and a potent hypoglycemic agent that improves insulin sensitivity (Shimoi et al., 
1998). Furthermore, Chung et al. (2001) indicated that luteolin showed a significant 
inhibition in Neisseria gonorrhoeae and Helicobactor pylori N-acetytransferase 
activity and their growth. 
 
2.5.5 Biological properties of quercetin  
 
  
 
       
Molecular formular : C15H10O 
Melting point : 314 
o
C 
Solubility : Soluble in glacial acetic acid, aqueous         
alkaline, alcohol, water and DMSO 
Appearance : Yellow needle (Susan, 1996) 
It is very well established that quercetin is chemically related to a class of 
flavonoids called anthocyanins.  Pharmacological studies indicated that quercetin 
possesses antihistamine, anti-inflammatory, antiallergic, and antiviral properties. In 
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addition, Wang et al. (1989) reported that quercetin was active against Bacillus cereus 
when present in the amounts of 2.5 µg/ml. Furthermore, quercertin has shown to 
cause chromosomal mutations in certain bacteria in in vitro study.   Kebieche et al. 
(2008) reported that quercetin at the dose of 0.33 mg/kg could protect liver cells and 
mitochondria from oxidative stress by maintaining normal levels of serum 
transaminases and preventing lipid peroxidation. 
Eumkeb et al. (2008) reported that when combined ampicillin, cloxacillin 
and ceftazidime with baicalein 5 µg/ml, MICs of these drugs against clinical isolates 
of MRSA were reduced from 100, >1,000 and 50 µg/ml to 5, 5 and 5 µg/ml, 
respectively. Furthermore, clinical isolates of ceftazidime-resistant Enterobacter 
cloacae (CREnC) with MICs of ceftazidime >1,000 µg/ml had their resistance to 
these drugs reversed by apigenin 5 µg/ml or luteolin 5 µg/ml to MICs of ceftazidime 
5 µg/ml. Viable counts showed that the killing of MRSA cells by 10 µg/ml ampicillin 
or cloxacillin was potentiated by 10 µg/ml baicalein. Ceftazidime 10 µg/ml in 
combination with 10 µg/ml of baicalein or galangin or quecertin also reduced the 
CFU/ml of MRSA to low levels (1 x 10
3
 CUF/ml) over 6 h. 
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2.6 Antibiotics 
2.6.1 Beta-lactam  
The β-lactam antibiotics are useful and frequently prescribed 
antimicrobial agents sharing a common structure and mechanism of action-inhibition 
of synthesis of the bacterial peptidoglycan cell wall (Laurence et al., 2006).  
 
2.6.2 Beta-lactam compounds 
2.6.2.1 Penicillins 
They are the most widely effective antibiotics and are among the 
least toxic drugs known; the major adverse reaction to penicillins is hypersensitivity. 
The members of this family differ from one another in the R substituent attached to 
the 6-aminopenicillanic acid residue. The nature of this side chain affects their 
antimicrobial spectrum, stability to stmach acid, and susceptibility to bacterial 
degradative enzymes (β-lactamases). Figure 2.1 shows the classification of agents 
affecting cell wall synthesis (Harvey et al., 2009). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
19 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.1  Summary of antimicrobial agents affecting cell wall synthesis. 
 Source: Harvey et al. (2009). 
 
2.6.2.2 Cephalosporins 
Cephalosporins are similar to penicillins, but more stable than 
many bacterial β-lactamases and therefore have a broader spectrum of activity. 
However, resistant strains of E. coli and Klebsiella species expressing extended-
spectrum β-lactamases that can hydrolyze most cephalosporins are becoming a 
problem. Cephalosporins are not active against enterococci and L. monocytogenes 
(Katzung, 2007). 
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2.7 The use of β-lactam antibiotics 
2.7.1 Cloxacillin 
                                   
 
 
 
 
 
 
 
 
Molecular formular : C19H18ClN3O5S
 
 
Molecular mass : 435.882 g/mol 
Solubility : Soluble in water  
Appearance : white or almost white, crystalline powder 
(http://en.wikipedia.org/wiki/Cloxacillin) 
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2.7.2 Ceftazidime 
                                            
 
 
 
 
 
 
 
Molecular formular: C22H22N6O7S2
 
 
Molecular mass : 546.58 g/mol 
Solubility: Soluble in water  
Appearance: white or almost white powder 
(http://en.wikipedia.org/wiki/Ceftazidime) 
                
2.8 Mechanisms of bacterial resistance to penicillins and 
cephalosporins 
Although all bacteria with cell walls contain PBPs, β-lactam antibiotics cannot 
kill or even inhibit all bacteria because bacteria develop various resistance to these 
agents. The microorganism may be intrinsically resistant because of structural 
differences in the PBPs that are the targets of these drugs. Furthermore, a sensitive 
strain may acquire resistance by the development of high-molecular-weight PBPs that 
decreased affinity for the antibiotic. Because the β-lactam antibiotics inhibit many 
different PBPs in a single bacterium, the affinity for β-lactam antibiotics of several 
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PBPs must decrease for the organism to be resistant. Altered PBPs with decreased 
affinity for β-lactam antibiotics are acquired by homologous recombination between 
PBP genes of different bacterial species. Four of the five high-molecular-weight PBPs 
of the most highly penicillin-resistant Streptococcus pneumoniae isolates have 
decreased affinity for β-lactam antibiotics as a result of interspecies homologous 
recombination events (Laurence et al., 2006).  
Bacteria can have an intrinsic immunity to a particular antibiotic because of 
biochemical structure and/or function. They may simply not respond to the antibiotic 
mechanism of action. Bacteria can also acquire resistance to a drug in one of two 
ways. Primary resistance occurs through spontaneous mutation, which is a rare event. 
Resistance is then transferred to progeny. Bacteria replicate asexually, so all offspring 
of a resistant bacteria will inherit the resistant gene. Secondary resistance requires a 
transfer of genetic material between same or different species of bacteria through 
transduction, transformation or conjugation (Table 2.1). Bacteria is asexual, bacteria 
can share genetic material by forming a conjugation bridge with bacteria from the 
same or different species (Figure 2.2). Genetic material is carried on plasmids or 
transporans. Genetic transfer may confer multi-drug resistance and cross-resistance, 
where by resistance to one drug in a class translates into resistance to other 
antimicrobial drugs in that class. The ease with which bacteria share genetic material 
accounts for most antimicrobial resistance (Roe et al., 2008). 
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Table  2.1  How bacteria transfer genetic material. 
 
 
How Bacteria Transfer Genetic Material 
Transduction Viruses carry genetic material from one bacterium to 
another 
Transformation Bacteria engulf genetic material from dead bacteria 
in the environment 
Conjugation                    
(most common) 
Two bacteria join cells and transfer genetic material 
via plasmids 
Source: Roe et al. (2008). 
 
 
 
 
 
 
 
 
 
 
                          
Figure  2.2  Bacterial conjugation. 
     Source: Roe et al. (2008). 
Once an antimicrobial enters the bacteria, it must bind to a specific biochemical 
target site in order to interfere with cell metabolism. Genetically altered bacteria can 
combat antibiotics in several ways (Figure 2.3). They may synthesize enzymes that 
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destroy the drug or chemically modify it so that it becomes inactive. For example, 
some β-lactamase, which destroys the bacteria, synthesize β-lactam ring common to 
the structure of β-lactam antibiotics. Resistance to the β-lactam is widespread in both 
Gram-positive (Staphylococci) and Gram-negative (Neissera gonorrhoea, 
Escherichia coli, and Haemophilus influenza) species. Some β-lactam antimicrobials, 
the antistaphylococcal penicilllins (methicillin, nafcillin, oxacillin, and dicloxacillin), 
were developed specifically to avoid the effects of the β-lactamase producing bacteria. 
Dicloxacillin is the only member of this group of antibiotics available in oral form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 Figure 2.3  Mechanisms of antibiotic resistance.  
                             Source: Roe et al. (2008). 
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2.9 Synergistic activities of flavonoid and β-lactam combinations 
The synergistic effects of β-lactam and flavonoid combinations against 
resistant bacteria may arise from contributions of three distinct types of activities. 
These could involve three mechanisms of action that galangin inhibit protein 
synthesis and effect on PBP 2a, interact with penicillinase and cause cytoplasmic 
membrane damage (Eumkeb et al., 2010). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 CHAPTER III 
MATERIALS AND METHODS 
 
3.1 Materials 
 3.1.1 Animals  
Male and female mice matched for age and weight were purchased from 
National Laboratory Animal Centre, Salaya Campus, Mahidol University, Thailand. 
The animals were housed in cages in the Animal Care Building at Suranaree 
University of Technology under a constant temperature of 25 ± 0.5 
o
C and hygiene 
conditions with 12 h. of light and dark cycle throughout the experimental period. The 
animals were provided free access to food and drinking water. 
 
3.1.2 Chemicals 
All chemicals used were analytical grade (AR) otherwise specified. 
    Dimethylsulfoxide (DMSO)     
    Sodium chloride       
    95% Ethanol      Lab grade 
    Formaldehyde 38% w/v     Lab grade 
    Cloxacillin        
    Ceftazidime        
    Apigenin       
    Baicalein        
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    Galangin        
    Luteolin        
    Quercetin        
 
3.1.3 Equipments 
Experimental glassware (pipette, volumetric flasks, beaker) 
Centrifuge tubes 
Autoclave 
Air pump; Benz aquarium pump 
EDTA tubes 
Sodium fluoride tubes 
Haematocrit tubes 
FTIR microspectroscopy 
 
 3.2 Methods 
3.2.1 Subacute toxicity test in mice 
The animals were divided into 24 groups. The group 1 and 12 to 14 were 
control groups (10 mice). The group 2 to 11 and 15 to 24 were tested groups (10 mice 
in each group) for each flavonoid alone and flavonoids in combination with β-lactams 
antibiotics. These mice were administrated by IP injection as follows:  
I. The group 2 to 11 were administered only flavonoids (apigenin, 
baicalein, luteolin, quercetin or galangin) at therapeutic dose (4 groups) 
and higher dose (4 groups) (Figure 3.1).  
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II. The group 15 to 24 were administered flavonoids in combination with 
β-Lactams (baicalein + cloxacillin, quercetin + cloxacillin, apigenin + 
ceftazidime, luteolin + ceftazidime, galangin + ceftazidime) at 
therapeutic dose (4 groups) and higher dose (4 groups) (Figure 3.2). 
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Figure 3.1  Subacute toxicity: Mice were administrated flavonoid alone. 
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Figure 3.2  Subacute toxicity: Mice were administrated flavonoids in combination 
  with β-Lactams. 
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All these groups were administered intraperitoneally 2 times a day for 2 
weeks. These mice were analyzed for the blood compositions before and after sample 
injection. At the end of the experiments, the animals were sacrificed under isoflurane 
anesthesia. The experimental protocol was followed in accordance with Breeding and 
Care of Laboratory Animals 1988 (Vol. 1)  prepared for the World Health 
Organization, Health Laboratory Technology Unit, Geneva, Switzerland and the 
procedures of the experiment was performed in accordance with the approvement of 
the animal laboratory ethical committee, Suranaree University of Technology. The 
body weights were evaluated every weeks. At the end of exposure course, the body 
and organ weights (lung, liver, kidney, spleen, heart and stomach) and organ 
morphology were evaluated. Hematological parameter was evaluated for the 
hematology (Hct, RBC, WBC and MCV) and blood chemistry (FBS, AST, BUN, 
cholesterol and uric acid). 
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3.2.2  Subchronic toxicity study 
The animals were divided into 22 groups. The group 1 and 10 to 12 were 
control groups (10 mice). The group 2 to 9 and 13 to 20 were tested groups (10 mice 
in each group) for each flavonoid alone and in combination with β-lactams antibiotics. 
These mice were administrated by IP injection as follows:  
III. The group 2 to 9 were administrated only flavonoids (apigenin, 
baicalein, luteolin or quercetin) at therapeutic dose (4 groups) and high 
dose (4 groups) (Figure 3.3). 
IV. The group 13 to 20 were administrated flavonoids in combination with 
β-Lactams (baicalein + cloxacillin, quercetin + cloxacillin, apigenin + 
ceftazidime, luteolin + ceftazidime) at therapeutic dose (4 groups) and 
higher dose (4 groups) higher treatment dose (Figure 3.4). 
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Figure 3.3  Subchronic toxicity : Mice were administrated flavonoid alone. 
 
 
 
 
 
 
 
 
 
Subchronic toxicity 
Control group 
Solvent (1) 
 
Tested groups 
 
Therapeutic doses 
 
Higher doses 
Apigenin 
(2) 
Baicalein 
(3) 
Quercetin 
(4) 
Luteolin 
(5) 
Luteolin 
(9) 
Quercetin 
(8) 
Baicalein 
(7) 
Apigenin 
(6) 
 
 
 
 
 
 
 
 
  
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Subchronic toxicity : Mice were administrated flavonoids in  
  combination with β-Lactams. 
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All these groups were administered intraperitoneally 2 times a day for 3 
months (90 days). These mice were analyzed for the blood composition before and 
after sample injection. At the end of the experiments, the animals were sacrificed 
under isoflurane anesthesia. The experimental protocol was followed in accordance 
with Breeding and Care of Laboratory Animals 1988 (Vol. 1)  prepared for the World 
Health Organization, Health Laboratory Technology Unit, Geneva, Switzerland and 
the procedures of the experiment was undertaked in accordance with the approvement 
of the Animal Care Building at Suranaree University of Technology. The body 
weights were evaluated every weeks. At the end of injection course, the result 
analysis was carried out by evaluating body weights, organ weights (lung, liver, 
kidney, spleen, heart and stomach) and organ morphology. Hematological parameter 
was evaluated for the hematology (Hct, RBC, WBC and MCV) and blood chemistry 
(FBS, AST, BUN, cholesterol and uric acid). 
 
3.2.3 Morphological examination 
At the end of the experiment, only the abnormal selected organs (lung, 
liver, kidney, spleen, heart or stomach) were fixed in 10% formalin, embedded in 
paraffin, sectioned, and stained with hematoxylin-eosin for pathological examination 
under light microscopy. In addition, the abnormal selected organs were cut into 1 mm 
cubes and fixed in 2.5% glutaraldehyde for 24 h at 4 ºC, sectioned with the 
ultramicrotome mounting a diamond knife. Sections of about 0.8 mm were collected 
on copper grids, stained for 3 min in 3% glutaraldehyde and 1% osmium tetroxide, 
then 2% uranyl acetate. This procedure was compared with normal selected organ  
(Hui et al., 2008). 
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3.2.4 Blood chemistry hematological analysis 
At the end of the experiment, blood samples were collected by cardiac 
puncture under ether anesthesia and were partly used for hematology. From the 
remainder blood serum was prepared by centrifugation at 1000 X g for 30 min and 
kept at –20 oC for blood chemistry analysis, including hemoglobin, WBC, RBC, 
HDL, serum bilirubin, blood glucose, cholesterol, triglyceride, AST, BUN and uric 
acid. The assays were performed with automated analytical systems. 
 
3.2.5 Fourier Transform Infrared (FTIR) microspectroscopy 
The experiments were performed at Synchrotron Light Research Institute   
utilizing a Tensor 27 FTIR spectrometer connected to an IR microscope (Hyperion 
2000). The microscope was equipped with a Mercury Cadmium Telluride (MCT) 
detector, with a 15x Cassegrain objective. FTIR samples were recorded in reflection 
mode, 8cm
-1
 spectral resolution, 128 scans per spectrum. 
 
3.2.5.1 Analytical potential of FTIR spectroscopy in biochemical  
     Characteristic frequencies, intensities, and band-widths in 
infrared spectra allow the identification of functional groups of molecules (Table 3.1) 
and the characterization of conformationally distinct structures in biological 
molecules (Fabian and Mantele, 2002; Naumann, 2000, 2001). IR spectroscopy was 
one of the earliest analytical methods identified as a powerful tool to gain information 
on the structural properties of proteins. As early as 1950 it was shown that there is a 
close correlation between the position of specific bands in the IR spectrum of 
polypeptides and their secondary structure. This correlation was later refined by 
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linking the frequencies of structure-sensitive amide bands to specific types of 
secondary structure such as α-helix, β-sheet, or turn (Fabian and Mantele, 2002). 
There are nine amide bands in the IR spectrum, called amide A, amide B and amides 
I–VII, according to decreasing frequency. The amide I band, in which different 
secondary structure elements such as α-helix, triple helix, β-sheet, β-turn, and 
extended coil absorb IR light of different wavelengths (Krimm and Bandekar, 1986), 
turned out to be the most useful band for the analysis of secondary protein structure. 
The amide I mode in IR spectra, which primarily represents the C=O stretching 
vibration of the amide groups and occurs in the region between 1600 and 1700 cm
-1
, 
is particularly sensitive to β-sheet structures. The position of IR bands associated with 
these structures is influenced by a variety of factors, including the strength of 
hydrogen bonds and the packing of β-strands (Surewicz and Mantsch, 1988; 
Zandomeneghi et al., 2004) (Figure 3.5).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Table 3.1 Tentative assignment of some bands frequently found in biological 
 FTIR spectra. 
 
Frequency (cm
-1
) 
 
Assignment 
~3500 O-H  str of hydroxyl groups 
~3200 N-H  str  (amide A) of protein 
2959 C-H  str  (asym) of –CH3 
2934 C-H  str  (asym) of  >CH2 
2921 C-H  str  (asym) of  >CH2  in fatty acids 
2898 C-H  str of →C-H  methine 
1741-1715 >C=O str of esters, >C=O str of carbonic acids, nucleic acids 
~1695, 
~1685, ~1675 
Amide I band components resulting from antiparallel pleated 
sheets and β-turns of proteins 
~1655 Amide I of α- helical structures 
~1637 Amide I of β- pleated sheet structures 
1548 Amide II 
1515 “Tyrosine” band 
1468 C-H def of >CH2 
~1400 C=O str (sym) of COO
-
 
1310-1240 Amide III band components of proteins 
1250-1220 P=O str (asym) of >PO2
-  
phospodiesters 
1200-900 C-O-C, C-O dominated by ring vibrations of carbohydrates  
C-O-P, P-O-P 
1085 P=O str (sym) of >PO2
-    
 
720 C-H rocking of >CH2 
900-600 “Fingerprint region” 
 
Source: Beekes et al. (2007). 
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 Figure 3.5  Representative spectrum in the mid-IR region. The region below 1500    
cm
-1
 is defined as the fingerprint region. The region above 1500 cm
-1
 is 
the functional group region. 
 Source: Hynes et al. (2005). 
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3.2.5.2 Serum samples analysis 
A diluted serum sample, 5-10 l, were dropped on a ZnSe 
window or deposited onto indium tin oxide-coated, silver-doped glass slide (low e-
slides, Kelvey slide) and vacuum dried for 24 h before analysis (Figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6      Diagram of the steps of serum preparation for FTIR microspectroscopy.  
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3.2.5.3 Multivariate data analysis 
Individual spectra from each cluster were analyzed using 
Principle Component Analysis to distinguish different biochemical component 
between serum from treatment and control groups. The spectra were processed using 
2º derivative, vector normalized by the Savitzky-Golay method (3
rd
 polynomial, 9 
smoothing points) using the Unscrambler 9.7 software. 
 
3.2.6 Statistical analysis 
All data were expressed as mean ± S.E.M. Significant differences between 
the control and treatment groups were analyzed by students t-test. P values <0.05 
were considered statistically significant. The significant differences between pre- and 
post-treatment groups were compared using Paired-Student t-test and statistiacal 
difference were determined at P<0.05. 
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CHAPTER IV 
RESULTS 
  
The study was divided into two parts. The first part is the subacute toxicity of 
the flavonoids (quercetin, apigenin, baicalein, luteolin, and galangin) use singly and 
combination with β-Lactams antibiotics (baicalein + cloxacillin, quercetin + 
cloxacillin, apigenin + ceftazidime, luteolin + ceftazidime, galangin + ceftazidime). 
These mice were injected intraperitoneal for 14 days. The second part shows the study 
of subchronic toxicity of the flavonoids (quercetin, apigenin, baicalein, or luteolin) 
alone and in combination with β-Lactams antibiotics (baicalein + cloxacillin, 
quercetin + cloxacillin, apigenin + ceftazidime, luteolin + ceftazidime, galangin + 
ceftazidime). These mice were administered by intraperitoneal injection for 90 days.  
 
4.1 Subacute toxicity test of some flavonoids 
4.1.1 Subacute toxicity test of quercetin 
4.1.1.1 Effects of the quercetin on weight changes and main organs 
in mice 
There was no significant difference in either the relative growth 
rate measured by living body weight (Figure 4.1) or the relative weight of the selected 
main body organs of all groups of treated mice for 14 consecutive days, when 
compared to the control (Table 4.1). The patho-histology of all organs showed normal 
appearance compared to the control organs (Data not shown). 
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group 2 (quercetin 80 mg/kg)
group 3 (quercetin  20 mg/kg+cloxacillin 150 mg
group 4 (quercetin 80 mg/kg+cloxacillin 600 mg/
control (cloxacillin 600 mg/kg)
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Body weights of mice treated with quercetin alone and in combination 
 with cloxacillin for 14 consecutive days in comparison with the negative 
 control. 
 
Figure 4.2 Morphology of main body organs of mice treated with quercetin alone and 
 in combination with cloxacillin for 14 consecutive days in comparison 
 with the negative control. Control group ; a =  heart; b = liver; c = spleen;        
d = lung; e = kidney; f = stomach. Treated group ; g = heart; h = liver; i =   
spleen; j = lung; k = kidney; l = stomach. 
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Table 4.1 Effects of intraperitoneally administered quercetin alone and in combination with cloxacillin for 14 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = quercetin 20 mg/kg 
BW/day, Group 2 = quercetin 80 mg/kg BW/day, Group 3 = quercetin 20 mg/kg BW/day plus cloxacillin 150 
mg/kg BW/day, Group 4 = quercetin 80 mg/kg BW/day plus cloxacillin 600 mg/kg BW/day, Cloxa = 
Cloxacillin (600 mg/kg BW). 
 
Organ (g) Control (NSS) Control Cloxa Group 1 Group 2 Group 3 Group 4 
Heart 0.0019 ± 0.0001 0.0018±0.0002 0.0022 ± 0.0001 0.0025 ± 0.0004 0.0017 ± 0.0003 0.0017 ± 0.0001 
Liver 0.0230 ± 0.0036 0.0185±0.0015 0.0239 ± 0.0018 0.0212 ± 0.0026 0.0196 ± 0.0011 0.0208 ± 0.0025 
Spleen 0.0053 ± 0.0017 0.0034±0.0001 0.0045 ± 0.0030 0.0020 ± 0.0001 0.0047 ± 0.0008 0.0049 ± 0.0008 
Lung 0.0029 ± 0.0002 0.0029±0.0003 0.0035 ± 0.0002 0.0030 ± 0.0003 0.0025 ± 0.0003 0.0024 ± 0.0003 
Kidney 0.0070 ± 0.0016 0.0064±0.0037 0.0079 ± 0.0008 0.0068 ±0.0013 0.0067 ± 0.0017 0.0059 ± 0.0002 
Stomach 0.0092 ± 0.0010 0.0097±0.0012 0.0107 ± 0.0018 0.0069 ± 0.0004 0.0127 ± 0.0036 0.0148 ± 0.0066 
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4.1.1.2 Effects of the quercetin for 14 days on blood chemistry and 
 hematology in mice 
 
The blood chemistry marker assayed indicated that there was no 
significant changes of AST, BUN, FBS, and cholesterol levels of all mice treated for 
fourteen days in comparison with pre-treatment groups (Table 4.2).  
In subacute toxicity test, results of hematology exhibited that 
there were no significant changes of WBC and Hct in post-treatment groups compared 
to pre-treatment groups. RBC and Hb levels decreased significantly after treatment 
with 80 mg/kg BW/day quercetin compared to the controls. MCV level also reduced 
dramatically after treatment with 20 mg/kg BW/day quercetin plus 150 mg/kg 
BW/day cloxacillin compared to the controls. 
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Table 4.2 Blood chemistry and hematological studies on mice before and after subacute treatment with quercetin alone 
and in combination with cloxacillin for 14 days.  Group 1 = quercetin 20 mg/kg BW/day, Group 2 = quercetin 
80 mg/kg BW/day, Group 3 = quercetin 20 mg/kg BW/day plus cloxacillin 150 mg/kg BW/day, Group 4 = 
quercetin 80 mg/kg BW/day plus cloxacillin 600 mg/kg BW/day, Cloxa = Cloxacillin (600 mg/kg BW). 
 
Parameter 
Control  (NSS) Control Cloxa. Group 1 Group 2 Group 3 Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 207.2±33.6 209.2±33.7 300.5±34.7 415.5±49.3 178.7±49.2 129.7±17.9 159.2±20.0 235.0±99.3 255.0±71.3 80.6±19.5 169.3±42.3 207.0±11.3 
BUN (mg/dl) 23.5±0.6 23.7±1.1 25.0±1.6 25.8±4.5 32.5±3.2 34.0±4.9 15.7±1.7 23.6±7.7 25.3±2.9 44.2±17.9 47.9±14.7 29.7±1.6 
FBS(mg/dl) 137.5±9.8 176.7±22.4 160.0±3.6 182.2±18.1 115.00±19.9 150.75±15.9 163.0±6.1 155.7±16.1 180.3±59.3 155.3±5.6 180.0±8.3 213.6±26.0 
Cholesterol(mg/dl) 85.2±2.7 92.0±4.1 129.0±8.0 116.5±13.7 100.0±4.5 162.2±54.6 105.0±7.0 151.0±49.8 134.6±20.1 84.6±19.6 106.6±38.6 78.6±07.5 
WBC (x103//µ L) 9.6±0.6 9.7±0.7 9.6±0.6 24.3±16.5 5.9±1.4 4.9±0.5 3.1±1.2 3.8±1.5 6.6±0.9 5.4±1.2 9.3±1.6 9.7±01.5 
RBC (x106 /µL) 9.0±0.1 8.9±0.4 9.05±0.1 8.9±0.4 7.8±0.4 8.2±0.1 8.7±0.3 6.7±0.0* 7.7±0.3 5.3±1.6 8.2±0.2 6.7±01.40 
Hb (g/dl) 15.5±0.2 14.5±0.2 15.5±0.2 14.5±0.2 13.3±0.9 14.2±0.5 15.1±0.3 10.5±1.0* 14.1±0.7 9.6±1.8 14.3±1.1 11.3±01.7 
Hct (%) 44.7±1.2 44.0±0.9 49.2±1.3 44.0±0.9 37.2±1.5 40.3±0.5 40.3±5.4 34.9±3.7 40.5±1.8 25.3±8.2 41.6±2.0 35.6±05.4 
MCV (fL) 54.5±0.8 54.2±0.7 54.5±0.8 52.9±0.7 48.2±0.4 49.2±0.4 51.0±0.5 45.3±2.3 52.0±2.0 47.1±0.6* 51.5±1.3 54.8±4.2 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value. 
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group 4  (baicalein  40 mg/kg+cloxacillin 600 mg/kg)
control (cloxacilin 600 mg/kg)
4.1.2 Subacute toxicity study of Baicalein 
4.1.2.1 Effects of the baicalein on weight changes and main organs in 
 mice 
 As demonstrated in Figure 4.3 and Table 4.3, treated mice of all 
groups did not significantly gain body and organ weights throughout 14 consecutive 
days, when compared to the control. The morphology of all selected treatment organs 
of mice exhibited a normal appearance in comparison with the control.  
   
  
 
 
 
 
 
 
 
 
 
 
 Figure 4.3  Body weights of mice treated with baicalein alone and in combination 
 with cloxacillin for 14 consecutive days in comparison with the negative 
 control. 
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Figure 4.4 Morphology of main body organs of mice treated with baicalein alone and 
 in combination with cloxacillin for 14 consecutive days in comparison 
 with the negative control. Control group ; a =  heart; b = liver; c = spleen;        
d = lung; e = kidney; f = stomach. Treated group ; g = heart; h = liver; i =   
spleen; j = lung; k = kidney; l = stomach. 
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Table 4.3 Effects of intraperitoneally administered baicalein alone and in combination with cloxacillin for 14 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = baicalein 10 mg/kg 
BW/day, Group 2 = baicalein 40 mg/kg BW/day, Group 3 = baicalein 10 mg/kg BW/day plus cloxacillin 150 
mg/kg BW/day, Group 4 = baicalein 40 mg/kg BW/day plus cloxacillin 600 mg/kg BW/day, Cloxa = 
Cloxacillin (600 mg/kg BW). 
 
Organ  (g) 
Control 
(0.2%DMSO) 
Control Cloxa Group 1 Group 2 Group 3 Group 4 
Heart 0.0019 ± 0.0001 0.0018±0.0001 0.0021 ± 0.0001 0.0019 ± 0.0001 0.0015 ± 0.0001 0.0018 ± 0.0001 
Liver 0.0193 ± 0.0011 0.0178±0.0010 0.0208 ± 0.0017 0.0185 ± 0.0013 0.0169 ± 0.0011 0.0198 ± 0.0008 
Spleen 0.0014 ± 0.0001 0.0014±0.0000 0.0017 ± 0.0001 0.0017 ± 0.0002 0.0013 ± 0.0001 0.0036 ± 0.0016 
Lung 0.0025 ± 0.0001 0.0025±0.0001 0.0025 ± 0.0001 0.0022 ± 0.0001 0.0028 ± 0.0003 0.0027 ± 0.0002 
Kidney 0.0072± 0.0010 0.0060±0.0006 0.0069 ± 0.0008 0.0062 ± 0.0005 0.0056 ± 0.0008 0.0057 ± 0.0007 
Stomach 0.0121 ± 0.0022 0.0069±0.0012 0.0179 ± 0.0025 0.0107  ±0.0021 0.0088 ± 0.0022 0.0112 ± 0.0020 
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4.1.2.2 Effects of the baicalein on blood chemistry  and hematology 
in mice 
 By the end of the study (14 days), blood chemistry finding were 
summarized in Table 4.4. There were no significant differences of AST, BUN and 
FBS levels in all groups of treated mice. 
Hb levels decreased significantly after treatment with 40 mg/kg 
BW/day baicalein plus 600 mg/kg cloxacillin BW/day compared to the control. The 
post-treatment MCV level also decreased significantly after treatment with 10 and 40 
mg/kg BW/day baicalein compared with pre-treatment.Conversely, there were no 
significant change of RBC and Hct levels in post-treatment groups compared to pre-
treatment groups (Table 4.4).   
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Table 4.4  Blood chemistry and hematological studies on mice before and after subacute treatment with baicalein alone 
and in combination with cloxacillin for 14 days.  Group 1 = baicalein 10 mg/kg BW/day, Group 2 = baicalein 
40 mg/kg BW/day, Group 3 = baicalein 10 mg/kg BW/day plus cloxacillin 150 mg/kg BW/day, Group 4 = 
baicalein 40 mg/kg BW/day plus cloxacillin 600 mg/kg BW/day, Cloxa = Cloxacillin (600 mg/kg BW). 
 
 
Parameter 
 
Control  
(0.20%DMSO) 
 
Control Cloxa.  
 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 312.5±80.0 615.1±189.1 276.0±36.3 301.0±48.9 156.8±19.9 478.6±155.2 222.0±35.6 256.6±47.3 271.4±47.4 271.0±47.3 400.2±85.0 608.4±152.9 
BUN (mg/dl) 27.2±3.2 22.5±1.6 26.2±1.8 25.7±3.4 21.0±2.8 20.5±3.5 29.1±2.6 27.52±2.53 21.8±3.0 19.82±1.16 21.48±3.20 22.26±1.36 
FBS(mg/dl) 160.7±6.6 191.4±15.7 160.4±2.8 181.2±14.0 158.4±20.6 180.8±15.7 153.2±12.0 185.6±11.0 168.6±13.5 175.2±13.6 171.00±18.3 166.20±7.2 
Cholesterol(mg/dl 140.3±21.6 135.7±22.3 141.0±13.5 105.0±9.7* 102.6±21.8 102.6±21.6 103.0±14.4 103.0±6.9 119.0±15.0 114.8±10.6 138.60±15.6 100.80±12.* 
WBC (x103//µ L) 9.6±0.8 5.0±1.7 9.7±0.7 4.5±0.64* 10.5±1.3 11.9±2.2 9.8±1.0 13.0±2.3 11.58±1.88 6.8±0.9 12.92±0.9 6.0±0.7* 
RBC (x106 /µL) 7.5±1.1 7.2±1.1 8.8±0.2 8.2±0.2 7.7±0.6 8.6±0.6 8.1±0.5 8.2±0.8 8.50±0.26 8.3±0.3 8.72±0.11 6.9±1.16 
Hb (g/dl) 15.5±0.5 13.0±1.7 15.5±0.2 14.5±0.2 14.0±0.7 14.4±1.0 14.8±0.5 14.2±1.3 15.0±0.31 14.8±0.3 15.60±0.50 12.0±1.5* 
Hct (%) 48.0±1.7 37.2±5.8 49.2±1.3 44.0±0.9 39.4±3.2 42.3±3.3 44.1±2.8 41.4±4.0 44.8±1.06 43.4±1.3 45.80±0.91 37.4±4.6 
MCV (fL) 51.5±0.2 50.7±1.0 54.5±0.8 53.0±0.9 50.8±0.7 48.7±0.5* 54.46±0.5 49.9±0.6* 52.9±1.38 51.9±0.4 52.50±0.78 51.1±6.0 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value.
5
1
 
 
 
 
 
 
 
 
 
52 
 
4.1.3 Subacute toxicity study of apigenin 
4.1.3.1 Effects of the apigenin on weight changes and main organs in 
 mice 
There were no significant differences in the relative body weight 
changes (Figure 4.5) and the relative weight changes of the selected main body organs 
of all groups of treated mice for 14 consecutive days, when compared to the control 
(Table 4.5). The morphology of all organs showed normal appearance compared to 
the control organs.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Body weights of mice treated with apigenin alone and in combination 
 with ceftazidime for 14 consecutive days in comparison with the negative 
 control. 
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Figure 4.6 Morphology of main body organs of mice treated with apigenin alone and 
 in combination with ceftazidime for 14 consecutive days in comparison 
 with the negative control. Control group ; a =  heart; b = liver; c = spleen;        
d = lung; e = kidney; f = stomach. Treated group ; g = heart; h = liver; i =   
spleen; j = lung; k = kidney; l = stomach. 
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Table 4.5  Effects of intraperitoneally administered apigenin alone and in combination with ceftazidime for 14 days on 
relative  weight of the selected main organ (per 100g body weight) in mice. Group 1 = apigenin 20 mg/kg 
BW/day, Group 2 =apigenin 80 mg/kg BW/day, Group 3 = apigenin 20 mg/kg BW/day plus ceftazidime 160 
mg/kg BW/day, Group 4 = apigenin 80 mg/kg BW/day plus ceftazidime 640 mg/kg BW/day, Cefta = 
Ceftazidime (640 mg/kg BW). 
 
Organ (g) 
Control 
(0.2%DMSO) 
Control Cefta Group 1 Group 2 Group 3 Group 4 
Heart 0.0019 ± 0.0001 0.0018±0.0001 0.0019 ± 0.0001 0.0017 ± 0.0001 0.0017 ± 0.0001 0.0094± 0.0049 
Liver 0.0179 ± 0.0014 0.0152±0.0016 0.0176 ± 0.0003 0.0187 ± 0.0006 0.0179 ± 0.0014 0.0176 ± 0.0005 
Spleen 0.0015 ± 0.0001 0.0021±0.0007 0.0026 ± 0.0008 0.0024 ± 0.0006 0.0020 ± 0.0005 0.0019 ± 0.0002 
Lung 0.0026 ± 0.0001 0.0027±0.0001 0.0028 ± 0.0003 0.0024 ± 0.0003 0.0026 ± 0.0001 0.0027 ± 0.0002 
Kidney 0.0065± 0.0007 0.0054±0.0008 0.0060 ± 0.0008 0.0064 ± 0.0006 0.0061 ± 0.0004 0.0062 ± 0.0007 
Stomach 0.0084 ± 0.0016 0.0089±0.0036 0.0139 ± 0.0047 0.0081  ±0.0010 0.0083 ± 0.0012 0.0081 ± 0.0012 
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4.1.3.2 Subacute toxicity effects of the apigenin on blood chemistry 
 and hematology in mice 
At the end of the experiments, blood samples were collected by 
tail under thiopental sodium anesthesia from 9.00 to 10.00 AM. and partly used for 
haematology. 
The blood chemistry marker assayed indicated that there were no 
statistical differences of all groups of mice treated with apigenin alone or in 
combination with ceftazidime (Table 4.6). 
          Results of haematology demonstrated that there were no 
significant changes of haematological parameters in post-treatment groups compared 
to pre-treatment groups.  
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Table 4.6  Blood chemistry and hematological studies on mice before and after subacute treatment with apigenin alone 
and in combination with ceftazidime for 14 days.  Group 1 = apigenin 20 mg/kg BW/day, Group 2 = apigenin 
80 mg/kg BW/day, Group 3 = apigenin 20 mg/kg BW/day plus ceftazidime 160 mg/kg BW/day, Group 4 = 
apigenin 80 mg/kg BW/day plus ceftazidime 640 mg/kg BW/day, Cefta = Ceftazidime (640 mg/kg BW). 
 
Parameter 
 
Control  
(0.20%DMSO) 
Control Cefta.  Group 1 Group 2 Group 3 Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 312.5±80.0 615.1±189.1 335.0±107.0 438.7±169.0 261.0±112.5 572.0±234.7 307.2±88.3 373.2±124.5 598.0±124.5 620.0±176.4 384.0±102 525.0±100 
BUN (mg/dl) 27.2±3.2 22.5±1.6 17.0±2.5 18.2±7.1 25.3±2.6 24.0±1.9 29.0±2.1 21.3±2.8 25.9±2.9 18.9±5.6 18.6±3.0 14.2±2.4 
FBS(mg/dl) 160.7±6.6 191.4±15.7 138.7±20.2 193.7±5.1 138.0±9.1 230.0±31.4 144.0±13.5 165.2±15.0 173.0±16.0 179.0±16.9 144.0±16.6 169.8±18.6 
Cholesterol(mg/dl) 140.3±21.6 135.7±22.3 212.5±7.5 276.2±40.2 105.0±31.3 118.0±7.0 115.8±27.9 88.6±8.5 178.0±30.0 236.2±45.0 164.0±30.4 229.0±9.1 
WBC (x10
3
//µ L) 9.6±0.8 8.0±1.7 9.6±0.9 4.8±1.8 10.4±0.63 5.7±1.8 12.6±1.2 12.5±1.3 9.8±0.7 8.0±0.7 7.5±0.9 5.9±0.9 
RBC (x10
6
 /µL) 7.5±1.1 7.2±1.1 7.7±1.2 7.2±1.1 8.5±0.0 7.3±0.5 8.4±0.5 7.8±0.1 8.0±0.6 7.9±0.6 8.9±0.3 6.6±1.0 
Hb (g/dl) 15.5±0.5 13.0±1.7 16.0±0.5 11.0±2.4 14.3±0.3 12.0±1.5 14.4±0.9 13.2±0.3 16.8±0.3 14.8±0.7 16.0±0.31 14.9±0.8 
Hct (%) 48.0±1.7 37.2±5.8 50.0±1.8 31.8±6.8 43.6±1.3 38.6±4.0 44.0±3.1 40.6±0.6 52.2±1.2 43.8±2.8 49.6±1.9 47.2±3.1 
MCV (fL) 51.5±0.2 50.7±1.0 51.0±0.3 51.0±1.2 50.5±1.4 50.4±1.6 51.1±1.1 51.2±0.6 52.7±0.7 54.3±1.9 52.1±0.5 51.0±0.3 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value.
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4.1.4 Subacute toxicity study of luteolin 
4.1.4.1 Effects of the luteolin on weight changes and main organs in 
 mice 
There were no significant differences in the relative growth 
changes of body and organ weights of all treated mice in comparison with the control 
(Figure 4.7) (Table 4.7). In addition, the morphology of organs of treated mice 
exhibited normal appearance compared to the control organs. 
   
  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Body weights of mice treated with luteolin alone and in combination with  
                ceftazidime for 14 consecutive days in comparison with the negative 
 control. 
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Figure 4.8 Morphology of main body organs of mice treated with luteolin alone and 
 in combination with ceftazidime for 14 consecutive days in comparison 
 with the negative control. Control group ; a =  heart; b = liver; c = spleen;        
d = lung; e = kidney; f = stomach. Treated group ; g = heart; h = liver; i =   
spleen; j = lung; k = kidney; l = stomach. 
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Table 4.7  Effects of intraperitoneally administered luteolin alone and in combination with ceftazidime for 14 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = luteolin 1 mg/kg 
BW/day, Group 2 = luteolin 4 mg/kg BW/day, Group 3 = luteolin 1 mg/kg BW/day plus ceftazidime 160 
mg/kg BW/day, Group 4 = luteolin 4 mg/kg BW/day plus ceftazidime 640 mg/kg BW/day, Cefta = 
Ceftazidime (640 mg/kg BW). 
 
Organ (g) 
Control 
(0.2% DMSO) 
Control Cefta Group 1 Group 2 Group 3 Group 4 
Heart 0.0014 ± 0.0001 0.0014±0.0000 0.0016 ± 0.0001 0.0014 ± 0.0001 0.0015 ± 0.0001 0.0015 ± 0.0002 
Liver 0.0169 ± 0.0017 0.0159±0.0012 0.0199 ± 0.0005 0.0182 ± 0.0012 0.0180 ± 0.0012 0.0168 ± 0.0017 
Spleen 0.0011 ± 0.0001 0.0012±0.0001 0.0013 ± 0.0001 0.0012 ± 0.0002 0.0027 ± 0.0006 0.0013 ± 0.0000 
Lung 0.0029 ± 0.0001 0.0027±0.0001 0.0025 ± 0.0001 0.0026 ± 0.0001 0.0025 ± 0.0001 0.0026 ± 0.0001 
Kidney 0.0046 ± 0.0014 0.0040±0.0009 0.0054 ± 0.0004 0.0054 ± 0.0006 0.0053 ± 0.0011 0.0050 ± 0.0011 
Stomach 0.0060 ± 0.0006 0.0063±0.0010 0.0209 ± 0.0059 0.0050  ±0.0004 0.0047 ± 0.0004 0.0046 ± 0.0005 
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4.1.4.2 Effects of the luteolin on blood chemistry  and hematology 
in mice 
The blood chemistry and heamatology marker assayed showed 
that there were no significant differences of all post-treatment groups compared to 
pre-treatment groups (Table 4.8). 
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Table 4.8 Blood chemistry and hematological studies on mice before and after subacute treatment with luteolin alone and 
in  combination with ceftazidime for 14 days. Group 1 = luteolin 1 mg/kg BW/day, Group 2 = luteolin 4 mg/kg 
BW/day, Group  3 = luteolin 1 mg/kg BW/day plus ceftazidime 160 mg/kg BW/day, Group 4 = luteolin 4 
mg/kg BW/day plus  ceftazidime 640 mg/kg BW/day, Cefta = Ceftazidime (640 mg/kg BW). 
 
 
Parameter 
Control  
(0.2%DMSO) 
 
Control Cefta. 
 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 207.2±33.6 209.2±33.7 207.3±18.4 209.0±19.8 369.6±108.4 452.0±61.3 349.8±77.2 731.0±377 272.0±154 703.3±109 207.3±18.4 249.3±48.4 
BUN (mg/dl) 23.5±0.6 23.7±1.1 22.0±2.5 21.0±2.0 20.3±1.2 23.4±2.5 23.8±1.7 22.0±2.78 18.2±1.3 23.8±1.7 22.0±2.54 25.6±4.0 
FBS(mg/dl) 137.5±9.8 176.7±22.4 175.6±3.7 176.6±4.4 157.2±9.1 175.2±15.8 194.4±7.1 199.8±4.4 133.3±50.9 190.0±8.6 154.0±11.0 176.6±4.4 
Cholesterol(mg/dl) 85.2±2.7 92.0±4.1 106.6±8.8 112.3±7.2 183.6±27.1 218.4±28.0 171.0±34.1 201.8±33.9 146.6±13.7 115.0±8.6 134.0±26.6 105.0±7.6 
WBC (x10
3
//µ L) 9.6±0.6 9.7±0.7 9.6±0.8 5.0±1.7 14.5±1.8 13.9±1.7 12.4±0.5 10.70±1.1 9.9±0.1 6.3±1.2 10.3±0.7 8.0±2.2 
RBC (x10
6
 /µL) 9.0±0.1 8.9±0.4 7.5±1.2 7.2±1.1 9.0±0.2 8.4±0.3 8.7±0.1 8.0±0.2 7.8±0.7 6.6±0.8 8.5±0.7 7.1±0.6 
Hb (g/dl) 15.5±0.2 14.5±0.2 15.5±0.5 13.0±1.7 15.4±0.4 14.8±0.3 15.4±0.2 13.8±0.5 15.6±1.2 12.0±1.1 15.6±0.6 12.6±1.2 
Hct (%) 44.7±1.2 44.0±0.9 48.0±1.7 37.3±5.8 45.4±1.5 39.0±2.6 46.6±0.8 41.8±1.5 48.6±4.4 39.0±4.0 50.3±2.4 39.3±3.1 
MCV (fL) 54.5±0.8 54.2±0.7 51.5±0.2 50.7±1.0 49.8±0.3 50.4±0.5 53.2±1.3 51.9±1.1 52.9±1.3 60.6±1.8 52.0±0.6 55.0±0.6 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value. 
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4.1.5 Subacute toxicity study of galangin 
4.1.5.1 Effects of the galangin on weight changes and main organs  in 
 mice 
There was no significant difference in either the relative growth 
rate measured by living body weight (Figure 4.9) or the relative weight of the selected 
main body organs of all groups of treated mice, when compared to the control (Table 
4.9). The patho-histology of the heart, liver, spleen, kidney, and stomach all revealed 
normal appearance compared to the control organs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Body weights of mice treated with galangin alone and in combination 
 with ceftazidime for 14 consecutive days in comparison with the negative 
 control. 
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Figure 4.10 Morphology of main body organs of mice treated with galangin alone 
and in combination with ceftazidime for 14 consecutive days in 
comparison with the negative control. Control group ; a =  heart; b = 
liver; c = spleen; d = lung; e = kidney; f = stomach. Treated group ; g = 
heart; h = liver; i =   spleen; j = lung; k = kidney; l = stomach. 
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Table 4.9 Effects of intraperitoneally administered galangin alone and in combination with ceftazidime for 14 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = galangin 10 mg/kg 
BW/day, Group 2 = galangin 20 mg/kg BW/day, Group 3 = galangin 10 mg/kg BW/day plus ceftazidime 160 
mg/kg BW/day, Group 4 = galangin 20 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = 
Ceftazidime (320 mg/kg BW). 
 
Organ (g) 
Control 
(0.2%DMSO) 
Control Cefta Group 1 Group 2 Group 3 Group 4 
Heart 0.0049 ± 0.0005 0.0045 ± 0.0004 0.0050 ± 0.0002 0.0052 ± 0.0002 0.0046 ± 0.0001 0.0045 ± 0.0004 
Liver 0.0514 ± 0.0029 0.0512 ± 0.0048 0.0498 ± 0.0032 0.0514 ± 0.0048 0.0474 ± 0.0012 0.0523 ± 0.0035 
Spleen 0.0041 ± 0.0005 0.0041 ± 0.0005 0.0045 ± 0.0004 0.0063 ± 0.0011 0.0040 ± 0.0005 0.0042 ± 0.0006 
Lung 0.0062 ± 0.0008 0.0061 ± 0.0007 0.0062 ± 0.0001 0.0062 ± 0.0003 0.0061 ± 0.0001 0.0062 ± 0.0003 
Kidney 0.0172 ± 0.0033 0.0170 ± 0.0034 0.0170 ± 0.0014 0.0163 ±0.0023 0.0165 ± 0.0023 0.0177 ± 0.0027 
Stomach 0.0199 ± 0.0035 0.0199 ± 0.00*5 0.0133 ± 0.0010 0.0223 ± 0.0037 0.0286 ± 0.0043 0.0231 ± 0.0042 
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4.1.5.2 Effects of the galangin on blood chemistry  and hematology 
in mice 
The blood chemistry marker assayed exhibited that there was a 
small decrease of AST and cholesterol level after treatment with galangin alone or in 
combination with ceftazidime compared to pre-treatment groups. However, the AST 
and cholesterol reduction were not significant difference at p<0.05. There was no 
clear dose-dependent or significant changes (p<0.05) of BUN and FBS between pre- 
and post-treatment in all groups (Table 4.10).      
Results of haematology demonstrated that there were no 
significant change of WBC, RBC, Hb, and MCV in post-treatment groups compared 
to pre-treatment groups. Conversely, the post-treatment Hct level exhibited clear 
dose-dependent and significant reduction (p<0.05) with increasing galangin and 
ceftazidime doses in comparison with pre-treatment in all groups (Table 4.10). 
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Table 4.10 Blood chemistry and hematological studies on mice before and after subacute treatment with galangin alone 
and in combination with ceftazidime for 14 days.  Group 1 = galangin 10 mg/kg BW/day, Group 2 = galangin 
20 mg/kg BW/day, Group 3 = galangin 10 mg/kg BW/day plus ceftazidime 160 mg/kg BW/day, Group 4 = 
galangin 20 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = Ceftazidime (320 mg/kg BW). 
 
Parameter 
 
Control 
(0.2% DMSO) 
 
Control Cefta. 
 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 207.2±33.6 209.2±33.7 118.4±13.3 118.2±13.4 150.8±4.0 149.4±3.9 139.2±8.2 109.4±12.3 153.0±24.2 111.4±5.9 118.4±13.3 97.2±4.4 
BUN (mg/dl) 23.5±0.6 23.7±1.1 20.4±2.1 16.7±0.4 21.4±1.4 15.8±2.1 16.5±1.0 22.0±4.1 25.3±1.4 24.4±1.2 22.4±2.1 16.7±0.4 
FBS(mg/dl) 137.5±9.8 176.7±22.4 103.2±25.9 103.8±3.4 108.4±19.13 154.0±8.2 109.6±22.7 87.2±10.1 114.8±20.9 115.8±5.0 103.2±25.9 139.8±3.4 
Cholesterol(mg/dl) 85.2±2.7 92.0±4.1 185.2±12.5 145.2±9.5 166.4±2.23 164.2±1.5 187.2±16.4 141.0±7.7 182.0±14.8 174.0±14.7 185.2±12.5 145.2±9.5 
WBC (x103//µ L) 9.6±0.6 9.7±0.7 6.5±0.3 5.6±0.9 8.0±0.5 7.1±0.7 7.2±1.1 7.60±1.7 5.9±0.5 4.7±0.3 6.5±0.3 5.6±0.9 
RBC (x106 /µL) 9.0±0.1 8.9±0.4 8.2±0.2 7.2±0.3 8.9±0.7 7.7±0.1 8.5±0.2 8.40±0.2 8.4±0.4 7.4±0.2 8.2±0.2 7.2±0.3 
Hb (g/dl) 15.5±0.2 14.5±0.2 14.5±0.8 12.2±0.6 13.9±0.6 12.6±0.2 12.7±0.2 12.0±0.2 14.0±0.7 12.6±0.6 14.5±0.8 12.2±0.6 
Hct (%) 44.7±1.2 44.0±0.9 53.1±1.7 53.2±2.4 54.8±1.3 45.5±0.6* 51.5±2.4 33.2±1.6* 51.3±0.6 38.8±2.0* 53.1±1.7 36.7±2.4* 
MCV (fL) 54.5±0.8 54.2±0.7 53.1±1.7 53.2±0.5 50.7±5.7 57.4±0.6 53.5±1.3 50.4±1.4 53.7±2.0 51.8±1.6 53.1±1.7 49.6±0.5 
 
Mean ± SEM (n=5), *p < 0.05 (Student’s t–test). Significant relative to pre-treatment value. 
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4.2 Subchronic toxicity test of some flavonoids 
4.2.1 Subchronic toxicity test of quercetin 
4.2.1.1 Effects of the quercetin on weight changes and main organs 
 in mice 
There was no significant difference in either the relative growth 
rate measured by living body weight (Figure 4.11) or the relative weight of the 
selected main body organs of all groups of treated mice for 90 consecutive days , 
when compared to the control (Table 4.11). The patho-histology of all organs showed 
normal appearance compared to the control organs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Body weights of mice treated with quercetin alone and in combination 
   with cloxacillin for 90 consecutive days in comparison with the negative 
   control. 
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Figure 4.12 Morphology of main body organs of mice treated with quercetin alone 
and in combination with cloxacillin for 90 consecutive days in 
comparison with the negative control. Control group ; a =  heart; b = 
liver; c = spleen; d = lung; e = kidney; f = stomach. Treated group ; g = 
heart; h = liver; i =   spleen; j = lung; k = kidney; l = stomach. 
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Table 4.11 Effects of intraperitoneally administered quercetin alone and in combination with cloxacillin for 90 days on 
relative  weight of the selected main organ (per 100g body weight) in mice. Group 1 = quercetin 20 mg/kg 
BW/day, Group 2 = quercetin 40 mg/kg BW/day, Group 3 = quercetin 20 mg/kg BW/day plus cloxacillin 150 
mg/kg BW/day,  Group 4 = quercetin 40 mg/kg BW/day plus cloxacillin 300 mg/kg BW/day, Cloxa = 
Cloxacillin (300 mg/kg BW). 
 
Organ (g) Control (NSS) Control Cloxa Group 1 Group 2 Group 3 Group 4 
Heart 0.0019 ± 0.0001 0.0016±0.0001 0.0017 ± 0.0002 0.0018 ± 0.0002 0.0019 ± 0.0001 0.0017 ± 0.0000 
Liver 0.0189 ± 0.0011 0.0173±0.0012 0.0162 ± 0.0019 0.0118 ± 0.0047 0.0213 ± 0.0010 0.0196 ± 0.0011 
Spleen 0.0017 ± 0.0001 0.0018±0.0001 0.0020 ± 0.0002 0.0063 ± 0.0034 0.0016 ± 0.0001 0.0051 ± 0.0034 
Lung 0.0027 ± 0.0001 0.0024±0.0001 0.0029 ± 0.0002 0.0025 ± 0.0001 0.0022 ± 0.0003 0.0023 ± 0.0001 
Kidney 0.0063 ± 0.0006 0.0055±0.0006 0.0068 ± 0.0022 0.0054 ± 0.0004 0.0317 ± 0.0254 0.0060 ± 0.0008 
Stomach 0.0063 ± 0.0013 0.0071±0.0009 0.0066 ± 0.0013 0.0086 ± 0.0024 0.0083 ± 0.0008 0.0094 ± 0.0022 
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4.2.1.2 Subchronic toxicity effects of the quercetin on blood 
 chemistry and hematology in mice 
Subchronic toxicity study indicated that AST and BUN levels 
slightly decreased except for the group treated with 40 mg/kg BW/day quercetin plus 
300 mg/kg BW/day cloxacillin, whereas FBS level decreased in all post-treatment 
groups compared to pre-treatment groups. However, there was no significant changes 
(p<0.05) of the levels between pre- and post-treatment in all groups (Table 4.12). 
Cholesterol level in post-treatment group exhibited a significant reduction in the 
group treated with 20 mg/kg BW/day quercetin plus 150 mg/kg BW/day cloxacillin 
compared to pre-treatment group. 
In subchronic toxicity test, results of hematology demonstrated 
that there were significant reductions of Hb (groups 1 and 2), Hct (groups 2 and 3) 
levels in post-treatment groups compared to pre-treatment groups. Conversely, MCV 
and RBC levels did not change in all groups. Also, the post-treatment WBC level 
exhibited no significant increase in comparison with pre-treatment in all groups 
(Table 4.12). 
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Table 4.12  Blood chemistry and hematological studies on mice before and after subchronic treatment with quercetin 
alone and in combination with cloxacillin for 90 days.  Group 1 = quercetin 20 mg/kg BW/day, Group 2 = 
quercetin 40 mg/kg  BW/day, Group 3 = quercetin 20 mg/kg BW/day plus cloxacillin 150 mg/kg BW/day, 
Group 4 = quercetin 40 mg/kg BW/day plus cloxacillin 300 mg/kg BW/day.BW/day, Cloxa = Cloxacillin 
(300 mg/kg BW). 
 
 
Parameter 
 
Control  (NSS) 
 
Control Cloxa.  
 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 235.2±2.9 235.5±3.3 133.5±7.3 173.2±31.8 190.2±49.2 128.5±7.5 181.7±29.2 147.0±16.6 257.7±92.0 249.0±45.4 185.6±52.2 361.3±118 
BUN (mg/dl) 23.5±0.6 23.7±0.6 26.5±3.3 25.5±1.0 33.7±2.5 33.0±2.6 33.0±1.9 27.9±1.9 37.2±10.8 20.4±2.9 19.0±1.8 23.5±3.1 
FBS(mg/dl) 138.0±9.3 142.2±7.6 186.0±13.6 216.7±3.0 151.7±7.1 153.0±9.1 180.0±22.4 180.5±40.9 168.5±4.9 224.2±22.2 195.3±27.1 224.3±41.3 
Cholesterol(mg/dl) 86.5±4.8 91.5±4.6 111.7±9.5 93.2±9.9 100.7±5.0 85.5±6.1 101.2±6.3 88.0±11.5 110.2±8.8 90.7±7.9* 107.0±20.8 100.0±5.2 
WBC (x103//µ L) 9.0±0.8 9.2±0.2 7.9±0.5 5.9±1.2 5.60±0.4 6.3±0.9 4.6±0.1 5.8±0.6 5.5±1.4 6.8±0.4 8.2±0.3 8.4±0.2 
RBC (x106 /µL) 9.0±0.1 9.2±0.2 7.3±0.3 6.2±0.4 5.6±04 6.3±0.9 5.8±04 6.0±0.9 5.5±1.4 6.8±0.4 8.2±0.3 7.9±2.0 
Hb (g/dl) 15.5±0.2 15.5±0.6 12.5±0.6 11.7±1.3 15.5±0.7 12.7±0.6* 13.5±0.5 11.0±0.0* 11.5±0.9 11.7±0.6 12.0±1.0 12.3±1.6 
Hct (%) 44.7±1.2 44.0±0.8 37.7±1.3 30.0±0.5 43.6±2.0 43.7±2.4 40.2±1.9 34.2±1.0* 38.2±1.7 34.0±2.6* 37.3±1.7 35.6±6.3 
MCV (fL) 53.2±0.4 53.5±0.2 51.5±1.1 47.5±0.6 50.5±0.6 50.0±1.0 49.9±0.3 53.6±3.2 47.4±1.9 48.9±0.5 51.4±0.4 49.2±1.5 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value. 
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4.2.2 Subchronic toxicity test of baicalein 
4.2.2.1 Effects of the baicalein on weight changes and main organs in 
 mice 
No significant difference was found in the relative growth rate 
and the relative weight of selected body organs of treated mice in all groups (Figure 
4.13 and Table 4.13). The morphology of all organs revealed normal appearance 
compared to the control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Body weights of mice treated with baicalein alone and in combination 
with cloxacillin for 90 consecutive days in comparison with the   
negative control. 
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Figure 4.14 Morphology of main body organs of mice treated with baicalein alone 
and in combination with cloxacillin for 90 consecutive days in 
comparison with the negative control. Control group ; a =  heart; b = 
liver; c = spleen; d = lung; e = kidney; f = stomach. Treated group ; g = 
heart; h = liver; i =   spleen; j = lung; k = kidney; l = stomach. 
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Table 4.13 Effects of intraperitoneally administered baicalein alone and in combination with cloxacillin for 90 days on 
relative  weight of the selected main organ (per 100g body weight) in mice. Group 1 = baicalein 10 mg/kg 
BW/day, Group 2 =  baicalein 20 mg/kg BW/day, Group 3 = baicalein 10 mg/kg BW/day plus cloxacillin 
150 mg/kg BW/day, Group 4 = baicalein 20 mg/kg BW/day plus cloxacillin 300 mg/kg BW/day, Cloxa = 
Cloxacillin (300 mg/kg BW). 
 
Organ (g) 
Control 
(0.2%DMSO) 
Control Cloxa Group 1 Group 2 Group 3 Group 4 
Heart 0.0017 ± 0.0001 0.0017±0.0000 0.0016 ± 0.0001 0.0018 ± 0.0001 0.0018 ± 0.0003 0.0016 ± 0.0001 
Liver 0.0187 ± 0.0007 0.0207±0.0021 0.0203 ± 0.0021 0.0200 ± 0.0018 0.0193 ± 0.0026 0.0160 ± 0.0017 
Spleen 0.0016 ± 0.0001 0.0046±0.0029 0.0046 ± 0.0029 0.0019 ± 0.0001 0.0022 ± 0.0005 0.0019 ± 0.0001 
Lung 0.0029 ± 0.0001 0.0033±0.0002 0.0033 ± 0.0002 0.0032 ± 0.0002 0.0029 ± 0.0004 0.0026 ± 0.0003 
Kidney 0.0060± 0.0005 0.0058±0.0007 0.0060 ± 0.0006 0.0062 ± 0.0011 0.0047 ± 0.0003 0.0055 ± 0.0006 
Stomach 0.0130 ± 0.0012 0.0138±0.0019 0.0135 ± 0.0022 0.0121  ±0.0015 0.0137 ± 0.0017 0.0146 ± 0.0023 
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4.2.2.2 Effects of the baicalein on blood chemistry and 
  hematology in mice 
The significant increase of BUN level was found in mice treated 
with 20 mg/kg BW/day baicalein alone or plus 300 mg/kg BW/day cloxacillin, 
whereas cholesterol level significantly decreased after treatment with 20 mg/kg 
BW/day baicalein alone and in combination with cloxacillin 300 mg/kg BW/day  
when compared to the pre-treatment group. However, there was no significant change 
of FBS and AST between pre-and post-treatment in all groups.  
The values of WBC and Hb in group treated with 20 mg/kg 
BW/day baicalein plus 300 mg/kg BW/day cloxacillin were significantly lower than 
those of the pre-treatment groups. RBC count decreased significantly in most all 
groups except in group that treated with 300 mg/kg BW cloxacillin alone and 10 
mg/kg BW/day baicalein plus 150 mg/kg BW/day cloxacillin, when compared to the 
pre-treatment groups. Hct level reduced in mice treated with 0.2% DMSO (control 
group), 20 mg/kg BW/day baicalein, and 10 mg/kg BW/day baicalein plus 150 mg/kg 
BW/day cloxacillin compare to pre-treatment group. Moreover, the post-treatment 
MCV level of mice treated with 10 and 20 mg/kg BW/day baicalein exhibited 
significant increase in comparison with pre-treatment group (Table 4.14). 
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Table 4.14 Blood chemistry and hematological studies on mice before and after subchronic treatment with baicalein 
alone and in combination with cloxacillin for90days. Group1=baicalein10mg/kgBW/day,Group2= baicalein 
20 mg/kg BW/day, Group 3 = baicalein 10 mg/kg BW/day plus cloxacillin 150 mg/kg BW/day, Group 4 = 
baicalein 20 mg/kg BW/day plus cloxacillin 300 mg/kg BW/day, Cloxa = Cloxacillin (300 mg/kg BW). 
 
Parameter 
Control  
(0.20%DMSO) 
Control Cloxa. Group 1 Group 2 Group 3 Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 411.8±86.0 552.4±73.7 300.5±34.7 415.5±49.3 416.5±61.5 416.0±61.6 509.8±86.4 525.0±89.0 513.3±35.2 528.6±8.8 528.0±113.9 583.2±66.4 
BUN (mg/dl) 28.4±2.1 23.1±3.2 25.0±1.6 25.8±4.5 24.2±2.6 40.25±7.6 22.8±2.0 27.0±2.6* 12.6±1.2 13.0±1.0 15.6±2.2 28.5±2.4* 
FBS(mg/dl) 162.2±9.4 157.2±10.2 160.0±3.6 182.2±18.1 118.0±10.5 136.2±13.9 176.8±19.8 165.0±12.9 210.0±10.0 144.3±8.7 172.0±18.5 146.4±13.4 
Cholesterol(mg/dl) 140.1±20.6 96.0±11.9 129.0±8.0 116.5±13.7 110.5±19.9 100.0±27.1 200.2±28.5 95.0±4.7* 190.0±15.2 190.3±15.0 156.0±19.3 92.8±9.3* 
WBC (x103//µ L) 9.7±0.9 9.0±0.8 9.6±0.6 24.3±16.5 8.55±1.33 10.2±2.8 7.8±1.4 6.5±1.7 4.8±1.0 4.8±1.0 12.9±1.9 7.8±1.7* 
RBC (x106 /µL) 9.2±0.1 7.8±0.2* 9.05±0.1 8.9±0.4 7.4±1.0 5.5±0.9* 8.8±0.1 7.6±0.2* 8.5±0.1 7.7±0.3 9.0±0.2 6.7±0.1* 
Hb (g/dl) 16.2±0.2 15.4±0.3 15.5±0.2 14.5±0.2 15.2±0.8 10.2±1.2 13.7±0.6 13.8±0.3 15.0±0.0 14.6±0.3 16.0±0.5 13.2±0.4* 
Hct (%) 49.1±1.6 39.9±1.1* 49.2±1.3 44.0±0.9 45.0±2.1 45.0±2.0 44.4±0.3 40.2±1.0* 46.0±1.0 39.6±4.2 47.6±1.2 36.2±1.6* 
MCV (fL) 52.0±0.6 51.7±0.3 54.5±0.8 52.9±0.7 49.9±0.5 52.1±0.8* 49.8±0.7 52.2±0.3* 53.8±0.7 53.6±1.2 53.0±1.1 53.3±1.5 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value.
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4.2.3 Subchronic toxicity test of apigenin 
4.2.3.1 Effects of the apigenin on weight changes and main organs in 
 mice 
 
There were no remarkable change in the relative growth rate 
measured by body weight and the relative weight of the selected organs of all groups 
of treated mice, compared to the control (Figure 4.15 and Table 4.15). Their 
morphology appearances were found normal compared to the control. 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 4.15  Body weights of mice treated with apigenin alone and in combination 
 with ceftazidime for 90 consecutive days in comparison with the 
negative control. 
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Figure 4.16  Morphology of main body organs of mice treated with quercetin alone 
and in combination with cloxacillin for 90 consecutive days in 
comparison with the negative control. Control group ; a =  heart; b = 
liver; c = spleen; d = lung; e = kidney; f = stomach. Treated group ; g = 
heart; h = liver; i =   spleen; j = lung; k = kidney; l = stomach. 
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Table 4.15 Effects of intraperitoneally administered apigenin alone and in combination with ceftazidime for 90 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = apigenin 20 mg/kg 
BW/day, Group 2 = apigenin 40 mg/kg BW/day,  Group 3 = apigenin 20 mg/kg BW/day plus ceftazidime 
160 mg/kg BW/day, Group 4 = apigenin 40 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = 
Ceftazidime (320 mg/kg BW). 
 
Organ (g) 
Control 
(0.2%DMSO) 
Control Cefta Group 1 Group 2 Group 3 Group 4 
Heart 0.0017 ± 0.0001 0.0018±0.0001 0.0017 ± 0.0001 0.0018 ± 0.0002 0.0015 ± 0.0001 0.0016 ± 0.0001 
Liver 0.0207 ± 0.0005 0.0202±0.0012 0.0188 ± 0.0017 0.0232 ± 0.0013 0.0207 ± 0.0002 0.0217 ± 0.0018 
Spleen 0.0015 ± 0.0001 0.0020±0.0003 0.0020 ± 0.0002 0.0019 ± 0.0001 0.0015 ± 0.0002 0.0018 ± 0.0001 
Lung 0.0027 ± 0.0001 0.0027±0.0002 0.0023 ± 0.0001 0.0030 ± 0.0002 0.0030 ± 0.0001 0.0028 ± 0.0002 
Kidney 0.0077± 0.0007 0.0072±0.0008 0.0060 ± 0.0009 0.0068 ± 0.0007 0.0062 ± 0.0000 0.0080 ± 0.0006 
Stomach 0.0150 ± 0.0025 0.0164±0.0049 0.0205 ± 0.0032 0.0114  ±0.0023 0.0078 ± 0.0021 0.0116 ± 0.0020 
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4.2.3.2 Effects of the apigenin on blood chemistry  and hematology 
in mice 
The results of blood chemistry analysis revealed that there was a 
significant increase of AST level after treatment with 320 mg/kg BW ceftazidime,  40 
mg/kg BW/day apigenin alone, or plus 320 mg/kg BW/day ceftazidime compared 
with pre-treatment. Cholesterol level decreased significantly in mice treated with 40 
mg/kg BW/day apigenin compared to pre-treatment. However, there were no 
significant change of BUN and FBS between pre- and post-treatment in all groups of 
subchronic toxicity test.  
Hematology data demonstrated that there was significantly 
reduced of WBC level after treatment with 40 mg/kg BW/day apigenin alone or plus 
320 mg/kg BW/day ceftazidime compared to pre-treatment groups. The RBC level of 
post-treatment in 0.2%DMSO (control), 40 mg/kg BW/day apigenin alone or plus 320 
mg/kg BW/day ceftazidime were significantly reduced compared with pre-treatment. 
In addition, The Hct  level of post-treatment in 0.2% DMSO (control), 320 mg/kg BW 
ceftazidime and 40 mg/kg BW apigenin plus 320 mg/kg BW/kg ceftazidime were 
significantly reduced compared to pre-treatment. Hb levels decreased significantly in 
mice treated with 40 mg/kg BW/day apigenin plus 320 mg/kg BW/kg ceftazidime 
compared to pre-treatment groups. MCV level was also significantly reduced in group 
of mice treated with 40 mg/kg BW/day apigenin alone compared to the pre-treatment 
group (Table 4.16). 
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Table 4.16  Chemistry and hematological studies on mice before and after subchronic treatment with apigenin alone and 
in combination with ceftazidime for 90 days.  Group 1 = apigenin 20 mg/kg BW/day, Group 2 = apigenin 40 
mg/kg BW/day, Group 3 = apigenin 20 mg/kg BW/day plus ceftazidime 160 mg/kg BW/day, Group 4 = 
apigenin 40 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = Ceftazidime (320 mg/kg BW). 
 
 
Parameter 
Control  
(0.20%DMSO) 
Control Cefta. Group 1 Group 2 Group 3 Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 411.8±86.0 552.4±73.7 248.7±43.6 450.0±63.5* 385.0±82.8 581.6±89.3 268.2±44.5 669.0±59.1* 450.0±80.1 532.8±80.9 301.0±33.5 526.8±53.5* 
BUN (mg/dl) 28.4±2.1 23.1±3.2 30.6±5.5 26.3±4.8 19.4±3.0 35.4±3.9 26.8±2.0 28.5±2.1 25.4±3.7 21.6±2.3 24.7±2.6 24.5±2.4 
FBS(mg/dl) 162.2±9.4 157.2±10.2 105.0±2.8 149.7±21.1 165.0±7.5 158.6±11.7 141.6±6.3 147.6±8.7 182.0±16.0 165.2±20.7 137.0±9.0 147.6±6.8 
Cholesterol(mg/dl) 140.1±20.6 96.0±11.9 141.3±33.9 169.7±40.9 177.0±26.7 147.2±36.5 282.2±29.4 86.0±5.9* 127.0±18.3 120.4±17.0 91.0±9.2 85.4±4.4 
WBC (x103//µ L) 9.7±0.9 9.0±0.8 8.1±1.9 5.4±0.5 16.0±1.3 16.0±1.2 8.4±0.9 3.7±0.6* 14.9±2.7 12.5±3.4 9.2±1.0 4.2±0.8* 
RBC (x106 /µL) 9.2±0.1 7.8±0.2* 8.8±0.4 7.2±0.5 9.0±0.3 7.6±0.7 7.95±1.0 6.5±1.1* 9.0±0.2 7.7±0.8 8.8±0.2 7.3±0.3* 
Hb (g/dl) 16.2±0.2 15.4±0.3 15.5±0.8 13.3±0.6 16.0±0.3 15.7±0.3 15.4±0.5 11.2±1.5 16.0±0.5 15.0±0.9 15.6±0.5 13.4±0.6* 
Hct (%) 49.1±1.6 39.9±1.1* 49.5±1.4 39.3±1.5* 49.2±0.9 48.7±0.9 47.4±1.6 32.8±5.5 48.8±2.1 41.5±4.8 45.6±1.5 38.2±2.1* 
MCV (fL) 52.0±0.6 51.7±0.3 55.9±1.2 54.5±1.5 51.7±0.3 49.6±0.6 51.3±0.2 49.7±0.3* 54.0±1.0 53.2±0.8 51.4±0.5 51.4±0.4 
 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value.
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4.2.4 Subchronic toxicity test of luteolin 
4.2.4.1 Effects of the luteolin on weight changes and main organs in 
 mice 
Body and organ weights of all treatment groups did not change 
for 90 days (Figure 4.17 and Table 4.17), which were similar to morphology 
appearance of treated mice. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Body weights of mice treated with luteolin alone and in combination 
with ceftazidime for 90 consecutive days in comparison with the 
negative control. 
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Figure 4.18 Morphology of main body organs of mice treated with luteolin alone 
and in combination with ceftazidime for 90 consecutive days in 
comparison with the negative control. Control group ; a =  heart; b = 
liver; c = spleen; d = lung; e = kidney; f = stomach. Treated group ; g = 
heart; h = liver; i =   spleen; j = lung; k = kidney; l = stomach. 
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Table 4.17 Effects of intraperitoneally administered luteolin alone and in combination with ceftazidime for 90 days on 
relative weight of the selected main organ (per 100g body weight) in mice. Group 1 = luteolin 1 mg/kg 
BW/day, Group 2 = luteolin 2 mg/kg BW/day, Group 3 = luteolin 1 mg/kg BW/day plus ceftazidime 160 
mg/kg BW/day, Group 4 = luteolin 2 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = 
Ceftazidime (320 mg/kg BW). 
 
Organ (g) 
Control 
(0.2%DMSO) 
Control Cefta Group 1 Group 2 Group 3 Group 4 
Heart 0.0017 ± 0.0001 0.0018±0.0001 0.0015 ± 0.0001 0.0016 ± 0.0001 0.0015 ± 0.0001 0.0016 ± 0.0001 
Liver 0.0154 ± 0.0012 0.0202±0.0012 0.0195 ± 0.0021 0.0186 ± 0.0011 0.0187 ± 0.0018 0.0185 ± 0.0011 
Spleen 0.0012 ± 0.0001 0.0012±0.0001 0.0014 ± 0.0001 0.0013 ± 0.001 0.0013 ± 0.0001 0.0014 ± 0.0001 
Lung 0.0027 ± 0.0001 0.0027±0.0002 0.0028 ± 0.0001 0.0026 ± 0.0001 0.0028 ± 0.0001 0.0026 ± 0.0001 
Kidney 0.0066 ± 0.0006 0.0072±0.0008 0.0061 ± 0.0007 0.059 ±0.0007 0.0061 ± 0.0007 0.0059 ± 0.0008 
Stomach 0.0151 ± 0.0025 0.0164±0.0049 0.0172 ± 0.0115 0.0057 ± 0.006 0.0056 ± 0.0004 0.0059 ± 0.0006 
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4.2.4.2 Subchronic toxicity effects of the luteolin for 90 days on blood 
 chemistry and hematology in mice 
Cholesterol, WBC, Hb, and MCV levels showed a significant 
reduction after treatment with 1 mg/kg BW/day luteolin plus 160 mg/kg BW/day 
ceftazidime and 2 mg/kg BW/day luteolin plus 320 mg/kg BW/day ceftazidime, 
compared to the pre-treatment groups. The Hct level of post-treatment in 0.2% DMSO 
(control), 1 mg/kg BW/day luteolin plus 160 mg/kg BW/day ceftazidime and 2 mg/kg 
BW/day luteolin plus 320 mg/kg BW/day ceftazidime were significantly reduced 
compared to pre-treatment. In addition, BUN level decreased dramatically in mice 
treated with 2 mg/kg BW/day luteolin plus 320 mg/kg BW/day ceftazidime compared 
to pre-treatment. Whereas, RBC count reduced significantly in the group treated with 
1 mg/kg BW/day luteolin plus 160 mg/kg WB/day ceftazidime compared to pre-
treatment groups. However, there was no significant differences (p<0.05) of AST and 
FBS levels between pre- and post-treatment in all groups of subchronic toxicity test 
(Table 4.18). 
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Table 4.18 Chemistry and hematological studies on mice before and after subchronic treatment with luteolin alone and 
in combination with ceftazidime for 90 days. Group 1 = luteolin 1 mg/kg BW/day, Group 2 = luteolin 2 
mg/kg BW/day, Group 3 = luteolin 1 mg/kg BW/day plus ceftazidime 160 mg/kg BW/day, Group 4 = 
luteolin 2 mg/kg BW/day plus ceftazidime 320 mg/kg BW/day, Cefta = Ceftazidime (320 mg/kg BW). 
 
 
Parameter 
 
Control  
(0.20%DMSO) 
 
Control Cefta.  
 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
AST (U/L) 411.8±86.0 552.4±73.7 253.7±16.3 375.0±98.3 358.6±81.9 360.0±81.4 467.0±85.0 469.4±86.3 284.0±24.4 284.0±20.7 296.0±76.0 296.0±75.0 
BUN (mg/dl) 28.4±2.1 23.1±3.2 31.3±8.8 18.0±2.6 21.6±1.9 20.8±1.9 15.4±1.0 15.6±1.0 32.2±1.3 23.7±2.6 27.4±1.4 15.4±1.0* 
FBS(mg/dl) 162.2±9.4 157.2±10.2 126.0±21.2 161.0±12.1 177.0±8.6 177.0±7.4 156.0±11.3 156.8±11.4 314.0±16.3 178.0±8.4 332.0±12.4 156.0±11.3 
Cholesterol(mg/dl) 140.1±20.6 96.0±11.9 191.6±109.2 93.0±16.5 130.0±20.3 128.6±20.6 100.0±9.6 99.0±9.2 414.0±13.6 190.0±12.9* 424.0±12.8 100.0±9.6* 
WBC (x103//µ L) 9.7±0.9 9.0±0.8 6.9±2.2 6.9±1.8 4.1±0.5 4.4±0.5 4.6±0.6 4.4±0.5 12.3±1.1 4.7±1.3* 13.5±1.0 4.4±0.7* 
RBC (x106 /µL) 9.2±0.1 7.8±0.2* 8.8±0.3 7.3±0.7 8.1±0.3 7.9±0.5 7.8±0.2 8.0±0.3 9.0±0.1 8.0±0.3* 8.7±0.2 7.7±0.1 
Hb (g/dl) 16.2±0.2 15.4±0.3 14.6±0.3 14.3±1.2 13.4±0.6 13.0±0.8 12.8±0.2 12.2±0.2 16.2±0.3 13.6±0.9* 15.6±0.6 12.8±0.2* 
Hct (%) 49.1±1.6 39.9±1.1* 47.6±0.8 40.3±2.7 41.4±1.5 41.6±1.6 40.2±0.5 40.4±0.2 48.8±0.9 42.0±2.2* 48.6±1.5 40.0±0.6* 
MCV (fL) 52.0±0.6 51.7±0.3 53.4±0.8 54.9±1.9 51.8±0.2 51.8±0.1 51.8±0.6 51.6±0.6 54.1±0.5 52.2±1.0* 55.7±0.9 51.7±0.7* 
 
Mean ± SEM (n=5), *p  < 0.05 (Student’s t–test). Significant relative to pre-treatment value. 
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4.3 Spectral differences between serums of normal and baicalein-
 treated mice (90 days) 
Serum samples of baicalein-treated mice was probed the spectral distribution 
compare to the control group by FTIR microspectroscopy combined with multivariate 
data analysis. Figures 4.19 and 4.20 demonstrated the two dimensional PCA 
clustering from FTIR data for serum samples of mice after treatment with 10 and 20 
mg/kg BW/day baicalein alone for 90 consecutive days,  respectively. It was found 
that serum samples of treated and normal mice were dramatically separated. The 
multivariate statistical analysis techniques based on PCA were used to statistical 
analyze the significant spectral data of serum samples of mice after treatment with 10 
and 20 mg/kg BW/day baicalein alone for 90 consecutive days, respectively. The 
loading from PC1 and PC2 of serum samples of mice after treatment with 10 mg/kg 
BW/day baicalein alone were accounted for 98% of the total variability. Whereas, the 
loading from PC1 and PC2 of serum samples of mice after treatment with 20 mg/kg 
BW/day baicalein alone were accounted for 92% of the total variability (PC1 69% 
and PC2 23%). 
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Figure 4.19 PCA analysis of spectra of serum samples of mice after treatment with 
10 mg/kg BW/day baicalein alone for 90 consecutive days. BT = 
treatment group, CT = control group. 
 
 
 
 
 
 
 
 
 
Figure 4.20 PCA analysis of spectra of serum samples of mice after treatment with 
20 mg/kg BW/day baicalein alone for 90 consecutive days. BH = 
treatment group, CH = control group. 
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The second derivative procedure in the 1800-1000 and 3050-2800 cm
-1
 regions 
(Figures 4.21 and 4.22) gave more insight into serum samples altered by the treatment 
compared to the control. The amide I and II bands showed a complex profile and their 
absorption are widely used to estimate the protein secondary structure. The presence 
of an amide I maximum near 1655 cm
-1
 in the two spectra indicated that the proteins 
adopt a predominantly α-helical configuration. Figure 4.21a exhibited that there was a 
change of the 10 mg/kg BW/day baicalein serum samples in the band of amide I near 
1655 cm
-1
, when compared to control spectrum. Indeed, this band was shift 
significantly from 1658 cm
-1 
to 1650 cm
-1
. The results imply that proteins in the serum 
samples including RBC were decreased.  
Figure 4.22a showed that there was the reduction of the amide I secondary 
structure component in sample serums treated with 20 mg/kg BW/day baicalein. The 
results seem consistent with previous results that RBC and Hct were decreased. The 
band of α-helix was shift to 1648 cm-1  compared to the control centered at 1650 cm-1. 
In addition, Figure 4.22b displayed the band centered at 2960 cm
-1
 and 2850 cm
-1
 
corresponding to stretching mode of asymmetric CH3, CH2 vibration provide evidence 
that cholesterol  was significantly decreased.  
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Figure 4.21 Representative 2
nd
 derivative transformation spectra (1800-1000 cm-1) 
of serum samples of mice treated with 10 mg/kg BW/day baicalein alone 
for 90 days (a) and 2
nd
 derivative transformation spectra (3050-2800 
cm
-1
) of serum samples of mice treated with 10 mg/kg BW/day baicalein 
alone for 90 days (b).  
 
 
 
(a) 
(b) 
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Figure 4.22 Representative 2
nd
 derivative transformation spectra (1800-1000 cm-1) 
of serum samples of mice treated with 20 mg/kg BW/day baicalein alone 
for 90 days (a) and 2
nd
 derivative transformation spectra (3050-2800 
cm
-1
) of serum  samples of mice treated with 20 mg/kg BW/day 
baicalein alone for 90 days (b). 
 
(a) 
(b) 
 
 
 
 
 
 
 
 
 CHAPTER V 
            DISCUSSION AND CONCLUSIONS 
 
The present studies investigated the toxicity effect of flavonoids on mice when 
use alone or in combination with β-lactams antibiotics including cloxacillin and 
ceftazidime. Flavonoids used in these studies are classified into 2 major subgroups 
(Flavone and flavonol) according to their chemical structures and major food sources 
(Moon et al., 2006). Flavone consists of apigenin, baicalein, and luteolin, whereas, 
galagin and quercetin are in flavonol group. 
In this study, quercetin was dissolved in 0.9% NaCl but apigenin, baicalein, 
luteolin, and galangin were dissolved in 0.20%DMSO for toxicity test. The test was 
included subacute and subchronic toxicity. Results clearly showed that there was no 
significant difference in either the relative growth rate measured by living body 
weight or the relative weight of the selected main body organs of mice treated with all 
doses of flavonoids alone or in combination with β-lactams antibiotics for 14 and 90 
days, when compared to the control. In subacute toxicity test, quercetin revealed 
significant reduction (p<0.05) of RBC and Hb in mice group treated with 80 mg/kg 
BW/day i.p. injection. Similarly, quercetin at 20 mg/kg BW/day plus cloxacillin 150 
mg/kg BW/day significantly reduced MCV level compared to pre-treatment group. 
Although a previous study indicated a relatively low-oral LD50 value for quercetin 
(i.e., in the range of 160 mg/kg body weight), the purity of the quercetin product 
administered was not specified, and subsequent longer-term animal toxicity showed 
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that quercetin was tolerated at oral dose levels exceeding this LD50 value by several 
fold. Moreover, no symptoms of toxicity were reported in rabbits receiving single 
intravenous injections of quercetin dose levels of 100-500 mg/kg body weight or two 
injections of up to 136 mg/kg body weight (Harwood et al., 2007). The MCV level 
significantly decreased after treatment with 10 and 40 mg/kg BW/day baicalein when 
compared to pre-treatment group. Moreover, this flavonoid at 40 mg/kg plus 
cloxacillin at 600 mg/kg significantly decreased cholesterol, WBC, and Hb level.  
These results can be explained by assuming that synergistic effect of baicalein and 
cloxacillin was occurred. The results of baicalein 10 mg/kg plus cloxacillin 150 
mg/kg not exhibited blood chemistry and hematological alteration on treated mice. 
From the results, it can be concluded that 10 and 20 mg/kg BW/day galangin 
i.p. injection showed discernable adverse effect upon mice relative growth rates and 
the selected main body organs changes in all mice. In addition, the results from blood 
chemistry exhibited no hazard on these mice groups. Similary, the toxicity of galangin 
at these concentration on WBC, RBC, Hb and MCV were not concern. The results of 
galangin on WBC presumably understand with those of Heo et al., 1994 who reported 
that galagin suppressed the induction of lymphocytes chromosome aberrations by 
bleomycin in a dose-dependent manner.  In contrast, galangin revealed significant 
reduction (p<0.05) of Hct after treatment in all mice groups as dose-dependent way 
(except ceftazidime treatment group). These results seem consistent with previous 
research that galangin in the lower doses of treatment (0.1 mg/kg) showed more 
potent anticlastogenic effect than in higher dose (10 mg/kg) from both single and 
multiple pre-treatment (Su et al., 1998). These findings provide evidence that high 
dose and long duration administration of galangin may result in Hct reduction.  
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Moreover, apigenin and luteolin in combination with ceftazidime at all doses revealed 
no toxicity on selected organs and blood parameters in mice when compared to pre-
treament group. Interestingly, luteolin has been investigated in vivo and in vitro with 
the focus on its potential adverse effects.  It  is  said  to  act  as  potent  inhibitor  of  
aromatase  and  β-hydroxysteroid oxidoreductase, which are enzymes involved in 
estrogen metabolism (Skibola and Smith, 2000).  In  addition,  it  was  shown  that  
luteolin-induced  cytotoxicity  in  isolated  rat hepatocytes  correlated  with  
mitochondrial  membrane  potential,  and  that  it  was  also slightly more toxic than 
the polyphenol chrysin towards the HeLa tumor cells (Moridani et al., 2002). 
Furthermore, Kotanidou et al. (2002) reported that the intra-peritoneal administration 
of a 50 mg/kg dose of luteolin was lethal to three of three mice receiving it. 
In subchronic toxicity test, results of haematology demonstrated that there were 
significant reductions of Hb in mice after treatment with quercetin 20 and 40 mg/kg 
BW/day. In particular,  Hct levels significantly declined in post-treatment groups with 
quercetin 40 mg/kg BW/day compared to pre-treatment groups. These results 
indicated that quercetin-treated mice may have anemia. Also, the post-treatment 
cholesterol and hematocrit exhibited  significant reduction in the group treated with 
20 mg/kg BW/day quercetin plus 150 mg/kg BW/day cloxacillin. These results are in 
substantial agreement with those of  Ruiz et al. (2006) that no variations were 
observed in a number of other standard toxicological parameters including body 
weights, food and water consumption, clinical chemistry, and organ weights in male 
and female Swiss mice administered quercetin in the diet at doses of 30, 300, or 3,000 
mg/kg BW/day for a period of 28 days in comparison to a control group. However, 
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our study conducted for 90 days may affect the toxicological parameters of treated 
mice.  
Apigenin, one of the most common flavonoids, is found in a variety of fruits 
and vegetables, including onions, parsley, and oranges as well as chamomile tea, 
wheat sprouts, and certain seasonings. Apigenin has demonstrated anti-inflammatory, 
anticarcinogenic, and free radial-scavenging activities in a variery of in vitro systems. 
It has been shown using animal models that allergic airway inflammation is increased 
by Th2 cytokine production and decreased Th1 cytokine production (Choi et al., 
2009). The results from subchronic toxicity test of apigenin showed that a significant 
reduction of cholesterol, WBC, RBC and MCV levels but significantly increased in 
AST in mice after treatment with 40 mg/kg BW/day apigenin when compared to the 
pre-treatment group, Furthermore, Mice receiving 40 mg/kg BW/day apigenin  plus 
320 mg/kg BW/day ceftazidime exhibited significantly decreased in RBC, Hb, Hct 
and WBC, Whereas AST was significantly increased. The RBC and Hct 0.2%DMSO 
post-treatment groups were also significantly decreased compared to pre-treatment 
groups. For this reason, RBC and Hct were remarkably decreased in the groups 
treatment with 40 mg/kg BW apigenin, and 40 mg/kg BW apigenin plus 320 mg/kg 
BW ceftazidime respectively, Never the less, there was prominently increased in AST 
levels after treatment with 320 mg/kg BW ceftazidime, 40 mg/kg BW apigenin and 40 
mg/kg BW apigenin plus 320 mg/kg BW ceftazidime. The reduction of cholesterol, 
WBC, and MCV after treatment with 40 mg/kg BW apigenin may cause by high dose 
and long duration of apigenin. The reduction of RBC and Hct level in mice treatment 
with 1 mg/kg BW luteolin plus 160 mg/kg BW ceftazidime and 2 mg/kg, BW luteolin 
plus 320 mg/kg BW ceftazidime may due to 0.2%DMSO that be used as solvent and 
 
 
 
 
 
 
 
 
 96 
also resulted in RBC and Hct decrease. Baicalein has been reported to have beneficial 
effects against benzoαpyrene-, aflatoxin (AF)-induced hepatic toxicity. It also has 
protective property against the cytotoxicity and genotoxicity of rat hepatocytes 
induced by tert-butyl hydroperoxide (t-BHP) due to its ability to quench free radicals 
(Hwang et al., 2005). The decrease of RBC and Hct levels in 20 mg/kg BW baicalein 
and 20 mg/kg BW baicalein plus 300 mg/kg BW cloxacillin treated mice may cause 
by 0.2%DMSO using as solvent and this also reduced RBC and Hct levels.  
The lowering of RBC, Hct and cholesterol in baicalein treated mice are in 
substantial agreement with the results from FTIR that the amide I secondary structure 
component was decreased. These results provide evidence that the amide I secondary 
structure, protein composition, is the component of RBC, Hct and cholesterol.  
In subchronic toxicity test, results of cholesterol level demonstrated that there 
were significant reductions in mice after treatment with 20 plus 150 mg/kg BW/day of 
quercetin plus cloxacillin, 20 mg/kg BW/day of baicalein alone, 20 plus 300 mg/kg 
BW/day of baicalein plus cloxacillin, 40 mg/kg BW/day of apigenin alone, 1 plus 
160, and 2 plus 300 mg/kg BW/day of luteolin plus ceftazidime, respectively.  
These finding lead us to believe that the high dose and long duration 
administration of these flavonoids result in blood cholesterol reduction. These results 
seem consistent with previous researches that flavonoids showed active  
hypoglycemic and hypolipidemic principle in many medicinal plants with blood 
glucose and lipids-lowering attributes (Oladele et al., 1995).  In addition, Birari et al. 
(2011) indicated the potential of the chalcone scaffold as a source of PL 
(triacylgycerol acyl hydrolase), inhibitors for preventing obesity. Dietary catechins 
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and anthocyanins significantly decrease the weight of abdominal adipose tissues 
(Murase et al., 2002; Tsuda, 2008). 
In conclusion, these findings lead us to believe that quercetin, apigenin and 
luteolin show no toxicity in blood chemistry, hematology and main organ in mice 
except for galangin causes Hct decrease and baicalein results in MCV reduction when 
these are administered at therapeutic dose for short duration. Interestingly, These 
flavonoids provide evidence that its can reduce cholesterol in mice blood when these 
are taken at hight dose for long duration. This study provides essential information for 
further investigation in other higher mammal, including human. 
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